Hydroxypyridinone Journey into Metal Chelation by Cilibrizzi, Agostino et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1021/acs.chemrev.8b0025
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Cilibrizzi, A., Abbate, V., Chen, Y-L., Ma, Y., Zhou, T., & Hider, R. C. (2018). Hydroxypyridinone Journey into
Metal Chelation. Chemical Reviews. https://doi.org/10.1021/acs.chemrev.8b0025
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
1 
 
The hydroxypyridinone (HOPO) journey into metal chelation  
Agostino Cilibrizzi,1* Vincenzo Abbate,1,2 Yu-Lin Chen,1 Yongmin Ma,3 Tao Zhou,4 and 
Robert C. Hider1 
 
1Institute of Pharmaceutical Science, King’s College London, Stamford Street, London 
SE1 9NH, UK 
2King’s Forensics, School of Population Health & Environmental Sciences, King’s 
College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH 
3College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, 
P. R. China, 311402 
4Department of Applied Chemistry, School of Food Science and Biotechnology, 
Zhejiang Gongshang University, Hangzhou, China, 310018 
 
* To whom correspondence should be addressed: 
Agostino Cilibrizzi  
Institute of Pharmaceutical Science  
King's College London  
5th Floor, Franklin-Wilkins Building  
150 Stamford Street  
London SE1 9NH  
Tel +44 (0)207 848 4501 
E-mail agostino.cilibrizzi@kcl.ac.uk  
 
2 
 
Abstract 
Hydroxypyridinones (HOPOs) form outstanding building blocks for the development of a 
variety of agents in the field of metal chelation. The pyridinone ring is easily synthesised 
and readily converted into tetradentate, hexadentate and octadentate chelators. There 
is considerable potential for the control of the stereochemistry of the resulting metal 
complex and hence the properties of these multidentate molecules. Their ability to 
rapidly bind hard metals in aqueous media has facilitated the development of efficient 
applications in both biological and medical contexts. In this review, an in-depth analysis 
of the synthetic methodologies for HOPO-based ligands is presented, as well as the 
many aspects to achieve optimal biological activity. Recent advances and current 
challenges for the future application of HOPO structures are outlined. The present 
flourishing development of drug candidates and diagnostic agents based on this 
chemical scaffold opens access to many new applications in analytical, environmental 
and clinical science.  
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1. Introduction: the origins of hydroxypyridinone (HOPO) selection for iron(III) 
chelation 
1.1. Design of orally active Iron chelators 
Iron is essential for almost all microorganisms, plants and animals by virtue of its unique 
chemical properties; namely the ability to coordinate and activate oxygen, and the 
possession of an ideal redox chemistry (FeII  FeIII  FeIV) for the facilitation of 
electron transport and metabolic processes.1 However iron is toxic when present in 
excess. In the presence of molecular oxygen, ‘loosely-bound’ iron is able to redox cycle 
between FeII and FeIII, thereby generating oxygen-derived free radicals, such as the 
hydroxyl radical.2 A number of protective strategies are adopted by cells to prevent such 
damage, including iron storage, tightly controlled iron transport and controlled 
distribution of iron. However, there are situations when these protective mechanisms 
become saturated, either locally in ischemic tissue, or systemically, as with transfusion-
induced iron overload. There is therefore a requirement for the selective removal of iron 
under such circumstances. Desferrioxamine-B (DFO, 1), the most widely used 
therapeutic iron chelator for many years, has a major disadvantage of not being orally 
active,3 consequently there has been a search for orally active iron-selective chelators 
since the early 1970s.  
Selection of appropriate ligands can be rationalised by adopting the concept of “hard” 
and “soft” acids and bases.4 High spin iron(III) is a tripositive cation of 0.65Å radius and 
as such is classified as a hard Lewis acid, by virtue of its high surface charge density. It 
forms stable bonds with charged oxygen atoms, such as phenolates. In contrast, the 
iron(II) cation has a lower charge density and favours nitrogen containing ligands. Such 
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ligands also bind other important divalent metals such as Cu(II) and Zn(II) with high 
affinity. In general, oxyanions are selective for tribasic metal cations over dibasic anions 
and as the majority of tribasic cations, for instance Al(III) and Ga(III), are not essential 
for living cells, iron(III) as opposed to iron(II), is the best target for ‘selective iron 
chelator’ design under biological conditions. A further advantage of high-affinity iron(III) 
chelators is that they chelate iron(II) and the resulting complex autoxidises under 
aerobic conditions to form iron(III).5 Thus high-affinity iron(III)-selective ligands 
scavenge both iron(III) and iron(II) under most physiological conditions.  
 
 
Figure 1. Octahedral iron complexes with six coordination sites. Bidentate ligands 
generate 3:1 complexes, tridentate ligands generate 2:1 complexes and hexadentate 
ligands generate 1:1 complexes.   
 
High spin iron(III) favours an octahedral stereochemistry and this can be achieved by a 
single hexadentate ligand, two tridentate ligands or three bidentate ligands (Figure 1). 
The majority of iron scavenging compounds found in living systems are hexadentate 
ligands as demonstrated by the wide range of siderophore structures.6 However as 
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most of these compounds are hydrophilic and possess molecular weights in excess of 
500, they possess low bioavailability via the oral route.7 Consequently, a search has 
been made for suitable bidentate and tridentate chelators, as these possess lower 
molecular weights and so are more likely to possess high oral biovailability.8 
 
1.2. Potential iron(III)-binding ligands 
A range of established iron(III) bidentate ligands is presented in Figure 2. 
 
 
Figure 2. Bidentate iron(III) ligands. 
 
1.2.1. Catechols  
Catechol residues possess a high affinity for tribasic metal ions resulting from the high 
electron density of both oxygen atoms. However, this pronounced charge density is also 
associated with a high affinity for protons (pKa values, 12.1 and 8.4).9 Therefore, the 
binding of cations by catechols is highly pH sensitive.10 For iron(III) the logK1 value is 20 
and the logβ3 value is 40 (see Section 3.1). With bidentate catechols, the 2:1 complex is 
the dominant form in the pH range 5.5-7.5.11 With such complexes, the iron atom is able 
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to interact with hydrogen peroxide or oxygen, possibly resulting in the generation of 
hydroxyl radicals. Moreover, catechol-based ligands are susceptible to oxidation.12 
 
1.2.2. Hydroxamates 
The hydroxamate moiety possesses a lower affinity for iron than catechol (logK1 = 11.4, 
logβ3 = 28), but selectivity, as with catechols, favours tribasic cations over dibasic 
cations.13 Due to lower protonation constants, hydrogen ion interference at physiological 
pH values is less pronounced than for catechol, consequently the 3:1 complex 
dominates at pH 7.4. However, the affinity for iron is insufficient to solubilise iron(III) at 
pH 7.4 and thus bidentate hydroxamates are not suitable biological iron scavengers. In 
contrast hexadentate hydroxamates, for instance DFO (1), are powerful iron(III) 
chelators. 
 
 
11 
 
1.2.3. 8-Hydroxyquinolines  
8-Hydroxyquinoline binds iron(III) tightly (logK1 = 13.7, logβ3 = 37). This ligand also 
binds iron(II) tightly as indicated by the relatively high oxidation potential (-150mV). This 
is a result of the presence of 3 nitrogen atoms in the 3:1 complex. The value of the 
oxidation potential indicates that iron complexes are likely to redox cycle under most 
biological conditions13 and indeed many 8-hydroxyquinolines are toxic. 
 
1.2.4. Aminocarboxylates 
Bidentate aminocarboxylates do not form tight complexes with iron(III) at neutral pH 
values (logK1 = 10) and are unable to successfully compete with the hydroxide anion. In 
contrast multidentate aminocarboxylates, for instance EDTA and DTPA, bind iron 
tightly, but not with high selectivity;14 Ca(II) and Zn(II) also binding tightly to EDTA. 
 
1.2.5. Hydroxycarboxylates 
α-Hydroxycarboxylates bind iron(III), indeed the alcohol function frequently dissociates 
on binding iron(III),15 in contrast to most other transition metals. However bidentate α-
hydroxycarboxylates, for instance lactic acid, possess a relatively weak affinity for 
iron(III) (logK1 = 2.9). In contrast, when incorporated in hexadentate siderophores, for 
instance rhizoferrin (2), they possess much higher affinities.16 
 
1.2.6. Hydroxypyridinones 
Hydroxypyridinones (HOPOs) combine the characteristics of both hydroxamate and 
catechol groups, forming 5-membered chelate rings in which the metal is coordinated by 
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two vicinal oxygen atoms. The hydroxypyridinones are monoprotic acids at pH 7.4 and 
thus form neutral tris-iron(III) complexes. The affinity of such compounds for iron(III) 
reflects the pKa values of the chelating oxygen atoms, the higher the affinity for iron(III), 
the higher the pKa value (Table 1).17,18 There are three classes of metal chelating 
HOPO ligands, namely 1-hydroxypyridin-2-one (1,2-HOPO; logK1 = 10.3, logβ3 = 27), 3-
hydroxypyridin-2-one (3,2-HOPO; logK1 = 11.7, logβ3 = 32) and 3-hydroxypyridin-4-one 
(3,4-HOPO; logK1 = 14.2, logβ3 = 37.2). Of these, the pyridin-4-ones possess the 
highest affinity for iron(III) (Table 1) and are selective for tribasic metal cations over 
dibasic cations. The surprisingly high pKa value of the carbonyl function of 3-
hydroxypyridin-4-one results from extensive delocalisation of the lone pair electrons 
associated with the ring nitrogen atom. 3-Hydroxypyridin-4-ones form neutral 3:1 
complexes with iron(III),19 which are stable over a wide range of pH values.18 The low 
redox potential of 3,4-HOPO iron complexes (-620 mV) indicates a strong bias towards 
iron(III) coordination.20 
 
1.3. Selection of an optimal bidentate iron-binding ligand class 
A useful parameter for the comparison of the ability of chelating agents to bind iron(III) 
is the pFe3+ value (concentration of free Fe(III) in solution, i.e. -log|Fe3+]), which is 
typically defined by the following conditions: [Fe3+]total, 10-6 M; [ligand]total, 10-5 M; pH 
7.4.21 Hydroxamates, 1,2-HOPOs and 3,2-HOPOs are not suitable scavenging 
bidentate chelators for iron as they do not possess a sufficiently high pFe3+ value to 
function as an iron scavenger (Table 1). Catechols are not suitable due to their 
tendency to form 2:1 complexes at neutral pH values. α-Amino- and α-
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hydroxycarboxylates do not compete efficiently with the hydroxide anion at neutral pH 
values. Iron complexes of 8-hydroxyquinolines are associated with the risk of redox 
cycling. This leaves 3-hydroxypyridin-4-one as the only bidentate ligand class presented 
in Figure 2 that is suitable for scavenging iron under biological conditions (see Section 
5.2.1.1). 
 
Table 1. pKa values and iron(III) affinity constants of acetohydroxamic acid and three 
different HOPOs. 
apFe3+= -log[Fe3+] when [Fe3+]total = 10-6 M and [ligand]total= 10-5 M at pH = 7.4. An ideal 
value for efficient iron scavenging in biological matrices is pFe3+ ≥ 20. Data sourced 
from references.17,18  
 
Ligand Structure pKa1 pKa2 logβ3 pFe3+ a 
Acetohydroxamic acid 
 
― 9.4 28.3 13 
1-Hydroxypyridin-2-one 
 
― 5.8 27 16 
1-Methyl-3-hydroxypyridin-2-one 
 
0.2 8.6 32 16 
1,2-Dimethyl-3-hydroxypyridin-4-
one   (deferiprone, (3)) 
 
3.6 9.9 37.2 20.5 
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1.4. Selection of optimal multidentate iron-binding ligands 
As indicated in the previous section, multidentate ligands are less likely to possess good 
oral activity, but they still have considerable potential as high affinity chelating agents for 
highly charged cations for instance Fe3+, Ga3+, Gd4+, Pu4+ (see Section 4). Furthermore, 
their utility as chelating agents is not limited to 3,4-HOPOs; like hydroxamates, 1,2-
HOPOs and 3,2-HOPOs when incorporated into multidentate ligands form powerful 
chelating agents. Thus, the design and synthesis of multidentate chelators is also a 
matter of some significance. Many naturally occurring hexadentate chelators 
(siderophores) which incorporate hydroxamate, catechol and α-hydroxycarboxylate 
functions are well characterized.6 The synthesis and properties of these molecules 
together with synthetic analogues have been reviewed.22-25 However analogues 
containing hydroxypyridinones have been less well covered and hence we overview 
such synthetic work in this review (Section 2). Hexadentate hydroxpyridinone chelating 
functions can adopt two broad structural designs, linear and tripodal (Figure 3). A range 
of tripodal bases are possible including cyclic esters, cyclic amides and sugars. Such 
molecules can also be capped (Figure 3). Synthetic approaches to these different 
structural designs are described in Section 2. 
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Figure 3. Structural design of hexadentate 3,4-HOPOs. 
 
2. Synthesis of hydroxypyridinones 
2.1. Bidentate 
2.1.1. N-Substituted 3-hydroxypyridin-4-ones  
The earliest record of the preparation of a 3-hydroxypyrid-4-one dates back to 193126 
when Armit and Nolan converted pyromeconic acid to the protected 3-hydroxy-1-methyl 
pyridin-4-one (Scheme 1A) via a double Michael addition reaction. This synthetic 
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approach has been widely adopted since that time, as reported by Kleipool and 
Wibaut,27 Heyns and Vogelsang,28 Berson et al,29 and Adams et al.30 It has been utilised 
for the synthesis of mimosine (4)31,32 and to prepare a range of 3-hydroxypyrid-4-ones 
with aliphatic N-substituents.33  
 
 
Scheme 1. A) Conversion of pyran-4-one to a 3,4-HOPO by reaction with an amine; B) 
substitution at position 1 of 3,4-HOPO by an alkyl function or protected sugar. 
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Although the double Michael addition occurs in acceptable yield without 3-hydroxy 
protection when non-bulky amines, for instance NH3 and methyl amine, are used as the 
nucleophile, lower yields result when more bulky amines are reacted. The double 
Michael addition involves sequential ring cleavage and ring closure (Scheme 1A) and 
presumably the more rapid the ring closure, the higher the yield of the desired product 
and the lower the corresponding yield of side products, resulting from polymerisation of 
the acyclic intermediate. More bulky amines are likely to slow the ring closure step, so 
enhancing the life time of the unsaturated acyclic intermediate, thereby encouraging 
polymerisation. A factor which leads to enhanced yields of the pyridin-4-one is the 
protection of the 3-hydroxyl function. In two studies which lacked 3-hydroxyl protection, 
the range of yields were reported to be 3-18%34 and 5-40%,35 whereas when the 3-
hydroxyl function was protected with, for instance a benzyl group, the range of yields 
was 53-84%.36 Such protection avoids the generation of an α-hydroxy ketone 
intermediate (Scheme 2), accumulation of which will increase the rate of intermolecular 
reaction, leading to polymer formation. The 3-hydroxyl function can be protected by the 
formation of a methyl ether37 or more commonly a benzyl ether.8,38,39 The methoxy 
group is typically cleaved by treatment with BBr3, whereas the benzyl group can be 
cleaved under more mild conditions, for instance with BCl3, catalytic hydrogenation or 
neat trifluoroacetic acid. This synthetic procedure has been reported in many 
patents.8,40-42 
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Scheme 2. Formation of α-hydroxy ketone intermediate. 
                                                         
 
An alternative route to N-substituted 3-hydroxypyridin-4-ones is from the corresponding 
unsubstituted pyridinone (Scheme 1B).43 This approach has been utilised for nucleoside 
synthesis, using trimethylsilyl intermediates (Scheme 1B).44-46 
 
2.1.2. 2-Substituted 3-hydroxypyridin-4-ones 
The Mannich reaction was first utilised by Taylor and coworkers for the preparation of 2-
substituted pyridin-4-ones.47 (Scheme 3A) This reaction also reaches high yields with 
the corresponding pyrones,47,48 which can then be subsequently converted to pyridin-4-
ones (Scheme 3A). The aldol reaction has also been utilised to functionalise position 2 
on pyromeconic acid and allomaltol (Scheme 3B) to provide a wide range of (1’-
hydroxyalkyl)-3-hydroxypyridin-4-ones39,49 using benzaldehyde dimethyl acetal as a 
protecting group.49 A convenient method for the production of 2-hydroxymethyl 
derivatives is via a pyridine N-oxide intermediate (Scheme 3C).50 The 2-hydroxymethyl 
substituent has been further utilised to conjugate additional moieties, for instance 
pegylated side chains51 and by conversion to the corresponding 2-aminomethyl 
derivatives and conversion to carboxylic acids with subsequent amidation (Scheme 
4).52-54 
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Scheme 3.  Synthesis of 2-substituted 3,4-HOPOs. A) Mannich reactions with 3,4-
HOPO and pyran-4-ones; B) aldol reaction with pyran-4-ones; C) preparation of 3,4-
HOPOs via pyridine-N-oxide intermediate. 
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Scheme 4. Synthesis of 2-carboxyamido-3,4-HOPOs. 
 
2.1.3. 5-Substituted 3-hydroxypyridin-4-ones 
Aminomethylation of 2-methyl-3-hydroxypyridin-4-ones leads to functionalisation of 
position 5,47  this approach has been utilised to produce an extensive range of 
substituted pyridin-4-ones (Scheme 5A).55 Position 5 can also be selectively brominated 
and then subsequently substituted by the methoxy group  (Scheme 5B).56  
 
Scheme 5. Synthesis of 5-substituted 3,4-HOPOs. 
 
 
2.1.4. 6-Substituted 3-hydroxypyridin-4-ones 
Kojic acid (5) is a convenient starting point for the synthesis of a range of 6-substituted 
pyridin-4-ones, for instance pegylated derivatives.51 In addition, oxidation and 
subsequent amide formation has led to the synthesis of a wide range of analogues 
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(Scheme 6A).57 6-Substituted-2-alkyl-3-hydroxypyridin-4-ones can also be prepared in a 
one-pot procedure from the parent pyridinone in good yield (Scheme 6B).58 
 
Scheme 6. Synthesis of 6-substituted 3,4-HOPOs. A) Conversion of kojic acid (5) to 6-
carboxyamido-3,4-HOPOs; B) conversion of 1,2-dialkyl-3,4-HOPOs to 6-arylamino-1,2-
dialkyl-3,4-HOPOs. 
 
2.1.5. Fluorine substituted 3-hydroxypyridin-4-ones 
A series of both 2-fluoro- and 5-fluoro-derivatives have been prepared from fluorinated 
pyridines.59,60 The general synthetic strategy for the synthesis of 2-fluoro derivatives is 
based on Li salt-catalysed aromatic hydroxylation and is presented in Scheme 7A. The 
strategy for synthesis of 5-fluoro derivatives is presented in Scheme 7B. Trifluoromethyl 
derivatives can be prepared in an analogous fashion.59  
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Scheme 7. Synthesis of fluorine-substituted 3,4-HOPOs. A) Synthesis of 2-fluoro-3,4-
HOPOs; B) synthesis of 3-fluoro-3,4-HOPOs. 
 
2.1.6. Methyl substituted 3-hydroxypyridin-4-ones  
The complete range of 1, 2, 5 and 6 monomethyl-3-hydroxypyridin-4-ones, 1,2,-; 1,5,-; 
1,6,- and 2,5,- dimethyl-3-hydroxypyridin-4-ones and 1,2,5-trimethyl-3- hydroxypyridin-
4-one have been synthesised61 in order to compare their properties with those of 
deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) (3), an iron chelator with wide clinical 
application (see Section 5.2.1.1).13,62 
 
2.1.7. Synthesis of bidentate 1-hydroxy- and 3-hydroxypyridin-2-ones 
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1-Hydroxypyridin-2-one can be directly nitrated to yield three different nitro derivatives 
(Scheme 8A)63-65 and 2 chloropyridine-N-oxide is a precursor of 4-alkoxy and 4-hydroxy 
derivatives (Scheme 8B).66,67  
 
Scheme 8. Synthesis of bidentate 1,2-HOPOs. 
 
 
6-Carboxy-1-hydroxypyridin-2-one, which is useful for the synthesis of oligopyridinone 
chelators (see Section 2.4.1.1), can be prepared from 2,6-dibromopyridine (Scheme 
24 
 
8C).68,69 1-Hydroxy-pyridin-2-ones can also be formed from acyclic precursors (Scheme 
9).70 
 
Scheme 9. Formation of a 1,2-HOPO from an acyclic precursor. 
                 
 
2,3-Dihydroxypyridine is a useful starting point for the synthesis of a wide range of 3-
hydroxypyridin-2-ones as initially reported by Mohrle and Weber.71 A series of N-
substituted derivatives have been prepared72 and derivatisation of the ring at the 4, 5 
and 6 positions is possible by use of the Mannich reaction (Scheme 10).47 A carboxyl 
function can be readily introduced at position 4 and this in turn can be amidated.73    
 
 
 
 
 
 
Scheme 10. Synthesis of bidentate 3,2-HOPOs. 
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2.2. Potential tridentate hydroxypyridinones 
In principle tridentate ligands are likely to be more kinetically stable than the 
corresponding bidentate analogues. Putative tridentate hydroxypyridin-4-one analogues 
were synthesised by the addition of either a phenol or carboxylate function at ring 
position 2 (Figure 4). 2-Aminomethyl-1,6-dimethyl-3-hydroxypyridin-4-one was 
condensed with a range of carboxylic acids via N-hydroxysuccinimide intermediates.52 
None of the compounds were found to bind iron(III) in tridentate mode, each favouring 
the formation of 3:1 complexes with the hydroxypyridin-4-one units binding iron in 
bidentate mode. 
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Figure 4. Potential tridentate 3,4-HOPOs. 
 
2.3. Tetradentate hydroxypyridinones 
There are two possible structures for the iron complexes of tetradentate 
hydroxypyridinones, 6 and 7, both with a metal:ligand ratio of 2:3 (Figure 5). Structure 6 
is apparently the most favoured form for both hydroxamate siderophores74 and 1-
hydroxypyridin-2-ones.75 With larger cations, for example europium(III), complexes with 
the metal to ligand ratio of 1:2 are formed (8).76 In contrast, with oxycation species such 
as UO22+ and MoO22+ stable 1:1 complexes result (9) (Figure 5). 
 
Figure 5. Possible structures for metal complexes of tetradentate hydroxypyridinones. 
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The majority of tetradentate 1,2-HOPOs are synthesised from 1-benzyloxy-6-
carboxypyridin-2-one (Scheme 11A), with the carboxylic acid function being activated 
for amide formation.76-78 Tetradentate 3,2-HOPOs have been designed for uranyl 
chelation79 and are largely based on the coupling of 4-carboxy-3-hydroxy-1-
methylpyridin-2-one to various diamines using identical coupling methods (Scheme 
11B).80 Tetradentate 3,4-HOPOs have also been developed by Santos et al for the 
chelation of molybdenum(VI)81 (Scheme 11C). 
 
Scheme 11. Synthesis of tetradentate HOPOs. 
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2.4. Hexadentate hydroxypyridinones  
As indicated in the introduction (Figure 3), there are three common basic structural 
designs for metal complexes formed from hexadentate hydroxypyridinones, tripodal, 
linear and capped tripodal. However, if the ligand structure is not optimal for 1:1 
hexadentate coordination, a 2:2 metal:ligand complex (10) may also form and even 
dominate.82 
 
 
 
2.4.1. Synthesis of tripodal hexadentate ligands 
2.4.1.1. 1-Hydroxypyridin-2-ones (1,2-HOPOs) 
6-Carboxy-1-hydroxypyridin-2-one is the main bidentate ligand adopted for tripod 1,2-
HOPO synthesis. It has been attached to a range of structures, including cyclic 
amines,83 tertiary amines,84 cyclic esters85 and aromatic amines73 (Scheme 12). 
Typically the 6-carboxy-1-hydroxypyridin-2-one is protected by the benzyl group and the 
carboxylic acid function is activated with 2-mercaptothiazoline for subsequent reaction 
with the tri-amines.84 Deprotection is generally achieved by treatment with HBr/AcOH. 
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Activation with pentachlorophenol has also been successfully utilised for such 
conjugations.85 Hybrid molecules containing both catechol and 1-hydroxypyridin-2-one 
ligands, for instance 11, have be prepared by stepwise addition of the activated ligands 
under high dilution conditions.84 3-Carboxy-2-hydroxyisoquinolin-1-one (12) has also 
been used to synthesise tripodal ligands,86 with the reported advantage that it is 
possible to readily form sulfonated derivatives which facilitate the water solubility of 
such ligands. 
 
 
 
 
 
 
 
 
 
 
30 
 
Scheme 12. Synthesis of hexadentate 1,2-HOPOs. A range of methods have been 
used to facilitate amide bond formation. 
 
 
2.4.1.2. 3-Hydroxypyridin-2-ones (3,2-HOPOs) 
4-Carboxy-3-hydroxy-1-methylpyridin-2-one has been used extensively to prepare 
tripodal chelators, using tertiary amines,87 cyclic amines88 and cyclic esters89 (Scheme 
13). 4-Carboxy-3-hydroxyl-1-methylpyridin-2-one is protected by the benzyl group and 
conjugated with 2-mercaptothiazoline before condensation with various tri-amines. 
Deprotection is achieved in HCl/AcOH at RT over two days.87 The corresponding acid 
chloride can also be utilised for the conjugation.89 Various derivatives of 3-
hydroxypyridin-2-one can also be utilised to form hexadentate ligands; for instance the 
1-(2’-hydroxyethyl) derivative (13) can be converted to an imidate salt which is capable 
of direct reaction with triamines (Scheme 14)90 and 1-carboxymethyl-3-hydroxypyridin-2-
one can be coupled to various triamines subsequent to activation with N-
hydroxysuccinimide72 or TBTU-facilitated condensation91 (Scheme 15).  
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A capped tripodal chelator based on 3-hydroxypyridin-2-one as the ligand has been 
prepared from 6-methyl-2,3-hydroxypyridinone dithiazolide (14) (Scheme 16)92 and a 
linear hexadentate ligand (15) has been synthesised  as a result of condensation of 4-
carboxy-3-hydroxyl-1-methylpyridin-2-one and spermidine. As with hexadentate 1-
hydroxypyridin-2-ones a range of hybrid molecules have been prepared with 
terephthalamide units.83,93 
 
 
 
Scheme 13. Synthesis of hexadentate 3,2-HOPOs using 4-carboxy-3-hydroxy-1-
methylpyridin-2-one as the chelating function. A range of methods have been used to 
facilitate amide bond formation.   
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Scheme 14. Synthesis of hexadentate 3,2-HOPO using 1-ethylene-3-hydroxypyridin-2-
one as the chelating function.  
 
 
Scheme 15. Synthesis of hexadentate 3,2-HOPOs using 1-carboxymethyl-3-
hydroxypyridin-2-one as the chelating function. A range of methods have been used to 
facilitate amide bond formation.  
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Scheme 16. Synthesis of capped hexadentate 3,2-HOPOs.  
 
 
2.4.1.3. 3-Hydroxypyridin-4-ones (3,4-HOPOs) 
Hexadentate 3-hydroxypyridin-4-ones, based on simple tripodal structures have been 
prepared via two major routes, one by direct conjugation of the protected pyridinone 
with tertiary nitrogen-based tripodal triamines (Scheme 17A)94,95 and a second utilising 
carbon-based tripodal triamines (Scheme 17B);96 the latter having the advantage of 
ready coupling to other biological active moieties for instance enzyme inhibitors or 
“address” systems (see Section 5).  
There are some reports of hexadentate 3-hydroxypyridin-4-ones being prepared directly 
from double Michael reactions.97-99 However, this leads to the tripodal base being 
attached to the 1-position of the 3-hydroxypyridin-4-one, which frequently generates a 
non-ideal stereochemistry for metal chelation. With wide tripodal structures such as that 
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provided by saturated carbocyclic rings, chelation in the hexadentate mode is possible, 
for instance with KEMP derivatives (e.g. 16). However with simple tripodal structures 
(17) a suitable orientation of the three coordinating units is more difficult to achieve, 
under which circumstances 2:2 complexes (10) may result.82 
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Scheme 17. Synthesis of tripodal hexadentate 3,4-HOPOs based on A) TRAM or 
TREN, and B) on ANPD.
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2.5. Octadentate hydroxypyridinones 
Tetrapodal ligands have been synthesised by coupling protected 1-hydroxypyridin-2-
ones to a range of tetrapodal amines (Scheme 18)100 and analogous linear octadentate 
chelators (18) have been prepared in a similar fashion.101,102 Hybrid linear chelators (19) 
have also been prepared.103,104 The tetrapodal 3-hydroxypyridin-4-one (20) has been 
synthesised by amide bond formation by performing the coupling in a microwave 
reactor. This procedure decreased the reaction time and increased the yield.105 
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Scheme 18. Synthesis of octadentate 1,2-HOPOs. 
 
 
2.6. Dendrimers    
Dendritic chelators are capable of binding large numbers of metal ions and may find 
application as metal sequestering agents for waste remediation and metal separation 
technologies. Raymond and co-workers reported the synthesis of salicylate-, 
catecholate-, and 3-hydroxypyridin-2-one functionalized dendrimers by attaching 
bidentate moieties to either poly(propyleneimine) or poly(amidoamine) dendrimers.106 
The synthesis of an example of a 3-hydroxypyridin-2-one-based dendrimeric chelator is 
presented in Scheme 19. 
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Scheme 19. Synthesis of PAMAM dendrimers conjugated with bidentate 3,2-HOPOs.  
 
The synthesis of a range of 3-hydroxypyridin-4-one hexadentate-containing dendrimers, 
together with the evaluation of their iron binding properties has also been reported. A 
first generation dendrimer (21) was prepared using a divergent synthetic strategy 
(Scheme 20).107 A convergent strategy was employed for the synthesis of a second 
generation dendrimeric chelator. In this case, a dendron containing three HOPO 
moieties (22) and multi-acid core (23) were combined to form dendrimer (24) (Scheme 
21).107 These dendrimeric chelators possess a high selectivity and affinity for iron(III).107 
The first generation dendrimer (25) which contains three hydroxypyridinone 
hexadentate moieties has been synthesised using a similar strategy (Scheme 22).108 
Dendrimer 25 includes amide functions adjacent to the coordinating phenolates, which 
contribute to the stability of the iron-complex via a hydrogen bond effect.109  
 
Scheme 20. Synthesis of first generation dendrimeric chelator (21) with 3,4-HOPO 
chelating groups. 
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Scheme 21. Synthesis of second generation dendrimeric chelator (24) with 3,4-HOPO 
chelating groups.  
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Scheme 22. Synthesis of first generation dendrimeric chelator (25) with 3,4-HOPO 
chelating groups. 
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2.7. Polymers    
As with dendritic chelators, polymeric chelators have potential for waste remediation 
and metal separation technologies. Hydroxypyridinone-functionalized Sepharoses have 
been synthesised in order to scavenge ‘hard’ metal ions. Both epoxy-activated- and 
CNBr-activated Sepharoses have been utilised to form gels with iron(III) chelating 
capacities between 200 and 500 μmol/g dry weight.110 A similar procedure utilising 1-
ethyl-3-hydroxy-2-methyl pyridin-4-one and mimosine (4) has also been used to prepare 
functionalized Sepharose.111 These gels possess a high affinity for hard metal cations, 
as typified by iron(III).112 
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A series of hydroxypyridinone-based iron binding resins have been synthesised; for 
instance, by copolymerisation of 1-(β-acrylamidoethyl)-3-hydroxy-2-methyl-4-(1H)-
pyridinone (AHMP) with 2-hydroxyethyl methacrylate and ethyleneglycol dimethacrylate 
as the crosslinking agent to form iron(III)-chelating beads (Scheme 23).113 Iron(III) 
chelating resins have also been synthesised by copolymerisation of AHMP with N,N-
dimethylacrylamide, and N,N’-ethylene-bis-acrylamide as a crosslinking agent (Scheme 
24).112 
 
Scheme 23. Synthesis of crosslinked 3,4-HOPO-containing polymers from AHMP and 
HEMA. 
 
 
 
Scheme 24. Synthesis of crosslinked 3,4-HOPO-containing polymers from AHMP and 
DMAA.  
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A series of linear poly(glycidyl methacrylate) (PGMA) polymers with well-defined 
properties and low polydispersities (PDI < 1.1) have been synthesized via RAFT 
polymerisation of GMA in the presence of CPBD as the chain-transfer agent. PGMA 
was conjugated with 3-hydroxypyridin-4-ones (3,4-HOPOs) containing free amino 
groups by a ring-opening reaction to generate a panel of HOPO-containing materials 
with controlled structures and specific iron-binding functions (Scheme 25).114 The 
synthetic method is simple with high yield and low cost, and thus the approach can be 
readily applied to the synthesis of related polymers. A hybrid 3,4-
ethylenedioxythiophene/thiophene precursor functionalized with an hydroxypyridinone 
group has been subjected to electropolymerisation.115 
Apart from the polymers on which some natural hexadentate ligands (such as DFO) are 
immobilised,116,117 other hexadentate chelator-containing polymers have rarely been 
reported. However the synthesis of 3-hydroxypyridin-4-one hexadentate ligand-
containing copolymers by copolymerisation of a 3-hydroxypyridin-4-one hexadentate 
ligand with N,N-dimethylacrylamide (DMAA), and N,N-ethylene-bis-acrylamide (EBAA) 
(Scheme 26), leads to copolymers which possess a high selectivity and affinity for 
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iron(III).118 A novel soluble 3-hydroxypyridin-4-one hexadentate based polymer has also 
been synthesised by copolymerisation of the hexadentate ligand with 2-hydroxyethyl 
acrylate (HEA) (Scheme 27).119 Hexadentate chelator-conjugated polymers have a 
distinct advantage over bidentate chelator conjugates in that they provide uniform metal 
chelating sites (Figure 6). Bidentate chelator-conjugated polymers lack a uniform high 
affinity for iron, because it is impossible for each bidentate moiety to form part of an 
ideal octahedral iron(III) coordination site. Thus the complexation of three bidentate 
ligands with iron will not be consistently strong and partial chelation of iron is likely.118 
 
Scheme 25. RAFT-based synthesis of PGMA-conjugated 3,4-HOPO-containing 
polymers. 
 
 
Scheme 26. Synthesis of hexadentate 3,4-HOPO-based chelating resin. 
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Scheme 27. Synthesis of hexadentate 3,4-HOPO-based chelating copolymer. 
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Figure 6. (a) Iron chelation by a bidentate ligand-containing polymeric chelator: three 
bidentate moieties bind one iron with ideal stereochemistry (left), only two bidentate 
moieties bind one iron and two coordination sites are occupied by water molecules 
(middle), three bidentate moieties bind one iron in a non-ideal geometry (right); (b) Iron 
chelation by a hexadentate ligand-containing polymeric chelator: all the hexadentate 
moieties bind iron with an ideal stereochemistry. Reproduced with permission from 
Ref.118. Copyright 2008 American Chemical Society.  
 
2.8. Hydroxypyridinone-based fluorescent probes 
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2.8.1. Coumarin-, benzothiazole- and fluorescein-linked bidentate 
hydroxypyridinones 
The most common fluorescent moieties used as metal sensors are coumarin, 
fluorescein and rhodamine.120,121 The coumarin molecule possesses strong 
fluorescence due to the presence of electron-donating groups at the 6- and 7-
positions.122 The synthetic route of such coumarin-linked bidentate hydroxypyridinones 
is summarised in Scheme 28.123 The coumarin acid is activated with 
dicyclohexylcarbodiimide (DCC) / 2-mercaptothiazoline, catalyzed by 4-
(dimethylamino)pyridine or DCC / N-hydroxysuccinimide (NHS) before coupling with an 
aminopyridinone. The aminopyridinones are typically synthesised from commercially 
available maltol or kojic acid via multistep reactions (Schemes 3 and 4).123 The amino 
group can be located in the 1-, 2-, 5- or 6-position of the pyridinone ring. After the 
methyl or benzyl protecting group of the resulting conjugate is removed, a range of 
fluorescent chelators is produced. The absorption and emission wavelengths of such 
probes fall in the ranges 325-432 nm and 380-474 nm, respectively. These probes are 
bidentate and chelate iron in a 3:1 ratio. The resulting fluorescence quenches on 
forming an iron complex.  
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Scheme 28. Synthesis of coumarin-linked bidentate 3,4-HOPOs.  
 
 
More specifically, a lysosomal targeting probe124 and a mitochondria-targeted probe125 
have also been synthesised. The syntheses of these compounds are presented in 
Schemes 29 and 30, respectively. Probe 26 is produced by coupling carboxylated 
fluorescein acid with an amine-based pyridinone in the presence of DCC/NHS (Scheme 
29); for the preparation of probes 27 and 28, the hydroxypyridinone component was 
coupled to the resin in position 2 or 4, respectively, using PyOxP/DIPEA chemistry. 
Prior to hydrazine treatment, the Fmoc-group on the N-terminus was removed and the 
resin treated with BOC2O/DIPEA in DMF. Following cleavage from the resin, probes 27 
and 28 were obtained following BCl3 treatment (Scheme 30).  
Orvig et al reported the synthesis of 1-(4-benzo[d]oxazol-2-yl)phenyl-3-hydroxy-2-
methylpyridin-4(1H)-one (29a) and 1-(4-benzo[d]thiazol-2-yl)phenyl-3-hydroxy-2-
methylpyridin-4(1H)-one (29b) to determine interaction with amyloid protein implicated 
in Alzheimer’s disease.126 The synthesis of these two compounds was initiated from 
maltol which coupled with 4-aminobenzoic acid, followed by cyclisation with 2-
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aminophenol or 2-aminobenzenethiol afforded the fluorescent chelators (29) (Scheme 
31). 
 
Scheme 29. Synthesis of a fluorescein-linked bidentate 3,4-HOPO. 
 
 
Scheme 30. Synthesis of peptide-based dansyl-linked bidentate 3,4-HOPOs. 
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Scheme 31. Synthesis of benzothiazole and benzoxazole functionalized 3,4-HOPOs. 
 
 
2.8.2. Bicyclic fluorescent hydroxypyridinones 
The introduction of fluorescent moieties appreciably influences the overall size of the 
probe molecule which is generally undesirable in biological studies. To minimise this 
effect, fluorescent probes have been synthesised where the optical moiety is merged 
with the chelating entity of the molecule.127,128 The synthetic procedure for the target 
fluorescent chelators is outlined in Scheme 32A. 3-Benzoxycomenic acid was prepared 
from kojic acid (5) by oxidation. The conversion of the pyranone to the corresponding 
bicyclic lactams was carried out by reaction with a range of diamino derivatives. The 
resulting bicyclic compounds were then hydrogenated in the presence of catalytic 
amounts of palladium to afford high yields of the desired fluorescent chelators (30). 
Chelator 30a can be further reacted using the procedures outlined in Scheme 32B. The 
position ortho to the enolic hydroxyl group can be functionalised in an analogous 
fashion to the aldol condensation, under alkaline aqueous conditions. Similarly, the 2-
position to the pyridinone ring is readily susceptible to aminomethylation by the Mannich 
reaction to form the corresponding aminomethyl derivatives. The emission wavelengths 
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of this type of probe are in the range of 454-470 nm and the average quantum yields 
are higher than those of coumarin-based probes.128  
 
Scheme 32. Synthesis of bicyclic fluorescent 3,4-HOPO probes. 
 
2.8.3. Hexadentate fluorescent hydroxypyridinones 
In addition to bidentate optical probes, a few hexadentate fluorescent agents have been 
reported.129,130 The syntheses of the coumarin-, fluorescein- and rhodamine-based 
hexadentate probes are presented in Schemes 33-35. Tri-tert-butoxycarbonylethyl 
methylamine (31) was treated with coumarin-3-carboxylic acid in DMF in the presence 
of DCC/HOBt, to form the coumarin-link. Hydrolysis of the resulting ester was achieved 
by treatment with formic acid, followed by activation of the triacid with DCC/NHS and 
coupled with aminopyridinones to furnish the corresponding protected coumarin-linked 
hexadentate molecules (Scheme 33). For fluorescein probes, tri-tert-
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butoxycarbonylethyl methylamine was initially coupled to β-alanine in the presence of 
DCC/HOBt, followed by deprotection to release the amino group. This amine group can 
couple with fluorescein isothiocyanate or activated fluorescein 5(6)-carboxylic acid. 
Following deprotection, the resulting triacid was coupled to an aminopyridinone and 
deprotected to yield the corresponding hexadentate probes129,130 (Scheme 34). In a 
similar manner, β-alanine was protected and coupled with tri-tert-butoxycarbonylethyl 
methylamine, followed by hydrolysis. The resulting triacid was coupled to an 
aminopyridinone, followed by the removal of the phthalimide protecting group to afford a 
free amine. This amine was coupled with rhodamine isothiocyanate and after 
deprotection, yielded the rhodamine-linked fluorescent probe (Scheme 35). 
 
Scheme 33. Synthesis of coumarin-based hexadentate 3,4-HOPO probes. 
 
 
Scheme 34. Synthesis of fluorescein-based hexadentate 3,4-HOPO probes. 
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Scheme 35. Synthesis of rhodamine-based hexadentate 3,4-HOPO probes. 
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2.8.4. Fluorescent hydroxypyridinone-containing beads 
A simple and fast method for the quantification of iron in serum has been developed 
using chelating fluorescent beads (CFBs). The synthetic route of the first generation 
CFB is shown in Scheme 36. The substituted pyridinone was treated with an equivalent 
of NHS-activated 3-maleimidopropionic acid to provide single substituted intermediate, 
where the free amino group reacts with NHS-activated 5(6)-carboxyfluorescein to form 
the benzyl protected compound. The benzyl group was deprotected using BCl3. This 
chelating probe (32) was covalently bound to Dynabeads. Incubation of the beads with 
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bovine serum albumin led to covalent binding of albumin to the beads via amino and 
thiol groups. The remaining albumin amino groups were reacted with Traut’s Reagent, 
and subsequently the thiol group from Traut’s reagent covalently bound to the iron 
sensor to afford the final probe-labelled beads (Scheme 36). These beads can be 
processed via a FACS instrument in order to provide information of the iron-content of 
solutions in which the beads have been incubated (see Section 5.1.1.3).131 Improved 
iron-sensitive beads were prepared using a hexadentate ligand (Scheme 37).107,123 
Lysine was selected as the linker between the beads, chelator and probe. The coupling 
of Fmoc-lys(Boc)-OH with the protected chelator via activation of the acid, followed by 
deprotection by hydrogenation leads to loss of the benzyl group, without influencing the 
Fmoc and Boc protected amines. The Boc group was then removed by trifluoroacetic 
acid, followed by coupling to Dynabeads. The Fmoc group was subsequently released 
by treatment with piperidine and the free amino group coupled with NHS activated 5(6)-
carboxyfluorescein to obtain the final chelatable fluorescent beads (Scheme 37). 
 
 
 
 
 
 
 
Scheme 36. Synthesis of bidentate 3,4-HOPO-containing fluorescent beads (CFBs). 
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Scheme 37. Synthesis of hexadentate 3,4-HOPO-containing fluorescent beads. 
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2.9. Considerations specific to HOPO synthetic chemistry 
In this section, we give a general overview of specific tips worthy of consideration when 
synthesising HOPO-based ligands. We highlight a number of practical aspects that will 
facilitate the efficient production of this class of chelator. We present a list of 
considerations for the optimisation of both synthetic and purification methods which are 
generally necessary to achieve the quality and amounts of chelator required for 
successful biological investigation. 
Chemical suppliers. Many of the reagents (e.g. starting materials) used in 
synthetic chemistry laboratories contain different traces of contaminants, depending on 
the brand and batch. Some of these contaminants are frequently metals or metal ions 
that can be complexed by the ligand under preparation. Attention should be paid to the 
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information relating to purity, procedure of purification and expected contaminants, as 
indicated by the specific supplier. 
Glassware. Particular care should be taken when cleaning the glassware. Metal 
spatulas and vials using caps with a metallic surface should be avoided as this is a 
potential source of metal contamination. The use of plastic spatulas to weigh both 
protected- and free-chelators is highly recommended. Moreover, each piece of 
glassware used in a chelator synthesis should firstly be acid treated with concentrated 
HCl (37%) and washed with methanol and dichloromethane, before drying.  
Analytical characterisation and purification procedures. Several 
analytical/purification methods have been adopted in the field of HOPO chelators, 
including precipitation and/or crystallisation from various solvents. Flash column 
chromatography can be used for protected bidentate ligands (pre-treatment of the 
stationary phase with EDTA is desirable); analytical/preparative TLC (i.e. plastic support 
sheet) and HPLC. HPLC presents numerous advantages as it can permit the rapid 
purification of free ligand. Also, in the case of tri- and tetra-podal HOPOs (i.e. 
hexadentate and octadentate ligands), preparative HPLC often represents the only 
option to obtain pure material. Crucial requirements for ideal HPLC procedures (both 
analytical and preparative) with regards to HOPO-based free ligands are:  
(i) perform a “wash run” of the system with a solution of 1mM EDTA, in order to 
minimise trace metal contamination during the following preparative/analytical run;  
(ii) use plastic tubes and plastic vial inserts to inject and/or collect the samples;  
(iii) use HPLC grade solvents (e.g. extra-pure MilliQ water, MeCN or MeOH).  
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In some cases, pre-treatment of the mobile phases with Chelex® is also required in 
order to avoid unwanted chelation of trace metals. Despite these measures, small 
amounts of metal complexes are nearly always detected during HPLC-based analyses 
and purifications. This contamination results from the metal parts associated with the 
equipment (e.g. column pumps, needles for injection and collection tubing). An HPLC 
unit with a titanium pump can be an advantage.    
Deprotection step. Removal of the protecting groups to unmask the chelating 
units is typically the final step in the synthesis of HOPO chelators. This step requires the 
above mentioned HCl pre-treatment of glassware to avoid the chelation of metals by the 
newly formed ligands. Typical procedures to remove specific protecting groups include: 
1) H2, Pd/C (benzyl removal); 2) BCl3 (benzyl removal; aluminum contamination has 
been detected when using this reagent, possibly due to traces present in the purchased 
batch); 3) BBr3 (methyl removal, benzyl removal that cannot be accomplished with 
BCl3); 4) neat trifluoroacetic acid (benzyl removal); 5) NH3OH 25% v/v (acetyl removal). 
Amide bond formation, coupling agents and solid-phase peptide synthesis 
(SPPS). Amino (see Scheme 3A) and carboxylate (see Scheme 4) functionalised 
HOPOs are the most common building blocks to generate oligomeric-HOPO chelators. 
These scaffolds are amenable to standard SPPS procedures. Commonly, unprotected 
chelators can be loaded on to the growing polypeptide chain immediately before the 
final cleavage from the resin. However, protected HOPOs can also be loaded on to the 
resin-attached peptide at any time during SPPS procedures and final deprotection (to 
unmask the chelating units) is usually performed in solution as the last step (see 
Scheme 30). Tripodal HOPO-based chelators (e.g. 22) have also been used in solid-
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phase synthesis, mainly in the unprotected form due to difficulties in fully accomplishing 
the final deprotection. Typical coupling reagents used include DIC, EDC, HATU, TBTU, 
PyOxP. Ethyl cyanoglyoxylate-2-oxime and HOBt are the usual auxiliary agents (i.e. 
anti-epimerisation) employed when standard carbodiimide are used, whereas DIPEA 
and Et3N are usually used as bases to favour the nucleophilic substitution. Amide 
coupling performance can be greatly facilitated by using microwave irradiation, both in 
terms of reaction rate and isolated yield of the desired product. For instance, the final 
step presented in Scheme 17 (i.e. reaction of a tri-COOH linker with a NH2-
functionalised HOPO) proceeds to completion within 30 minutes, with the minimal 
occurrence of side reactions and producing a final yield of 70% for the desired product 
when subjected to microwave conditions. In the absence of microwave irradiation, the 
reaction took over two days to reach completion and was associated with a much 
reduced yield.  
 
3. Physico-chemical properties of hydroxypyridinones  
3.1. Thermodynamic stability constants  
Thermodynamic stability constants are the main indicators for chelator metal affinities. 
In aqueous solution, apart from metal ions, protons, can compete for chelators. For 
many trivalent metal ions, including iron(III), the optimal coordination number is six, 
which requires three bidentate or one hexadentate chelator to form a stable metal 
complex (Figure 1). The dominant chemical equations and corresponding 
equilibrium/stability constants of metal-chelation reactions for 3-hydroxypyridin-4-ones, 
e.g. deferiprone (3), are listed in Scheme 38. Deferiprone (3) possesses two pKa values, 
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3.7 and 9.8, over the pH 2-12 range and forms a stable iron complex at pH 7.4 with the 
molar ratio of ligand:ferric iron being 3:1, logβ3(Fe3+) = 37.418 (Table 2 and Figure 7). In 
general, the higher proton affinity a chelator possesses, the higher its metal affinity. This 
observation is demonstrated by the existence of a linear relationship between 
logK1(Fe3+) and sum of two pKa values for 3-hydroxypyridin-4-ones (Figure 8).  
 
 
Figure 7. Optimised Fe3+L3 structure of deferiprone, left-hand propeller (lambda), Fac(e) 
stereoisomer. Reproduced with permission from Ref.17. Copyright 2002 John Wiley & 
Sons, Inc.  
 
 
 
 
 
62 
 
Scheme 38. Typical stability constants of a bidentate 3-hydroxypyridin-4-one. 2 pKas 
values and 3 metal logK equilibrium equations describe the metal-HOPO interaction; L: 
ligand, M: metal, β3 is a cumulative constant; charges of species are neglected for 
simplicity. 
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63 
 
 
Figure 8. logK1(Fe3+) values versus sum of pKa values for 57 3,4-HOPOs. Reproduced 
from Ref.132 with permission from the Royal Society of Chemistry.  
 
Another example for this relationship is the trend between logβ3(Fe3+) and pKa values of 
hydroxypyridinone analogues (Table 1). The superior affinity of deferiprone for metals 
results from the extensive delocalisation of electrons in its resonance structures (Figure 
9). Because of the competition effect at different pH values in aqueous solution Since 
the HOPO chelators differ in the denticity of their metal coordination and also in their 
relative acidities, metal stability constants are not directly comparable for all the ligands. 
The pM value (normally defined as -log[free hydrated metal], when [Ligand]total = 10-5 M 
and [Metal]total = 10-6 M, at pH 7.4) is introduced as a comparative indicator.21 This term 
is calculated from the associated stability constants and multiple equilibria amongst the 
various chemical species, under defined conditions. The pM value changes as a 
function of [Metal], [Ligand] and pH. This is clearly shown in Ringbom coefficients,133 
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derived from the mass balance equation of associated chemical reactions, as part of pM 
calculation (the ligand Ringbom coefficient is exemplified in Scheme 39). The influence 
of pH on pM values is illustrated by the pFe3+ value of deferiprone (3) over the pH range 
2-12 (Figure 10).  
 
 
Figure 9. Proton equilibria and resonance structures of deferiprone (3), a typical N-
alkyl-3,4-HOPO with 2 pKa values. 
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Figure 10. pH dependence of the pFe3+ value of deferiprone (3) under the conditions of 
[deferiprone]total = 10-5 M and [Fe3+]total = 10-6 M (solid line), compared to pFe3+ values of 
iron hydroxide species (dashed line). The formation constants of hydroxide species are 
as follows: logK FeOH = 11.2, logK Fe(OH)2 = 22.3, logK Fe(OH)3 (s) = -38.8, logK 
Fe(OH)4 = 34.4, logK Fe2(OH)2  = 24.7, logK Fe3(OH)4 = 49.7.134 
 
 
Scheme 39. Ligand Ringbom coefficient (αL) from the mass balance equation of ligand, 
Kf: formation constant, the inverse form of conventional acid equilibrium constant. 
Ltotal = [L] + [LH] + [LH2] + … 
Ltotal = [L] + Kf1[L][H] + βf2[L][H]2 + … 
Ltotal = [L]( 1 + Kf1[H] + βf2[H]2 + …) 
αL= 1 + Kf1[H] + βf2[H]2 + … 
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Table 2. Stability constant of selected HOPOs. Affinity constants data taken from 
references18,135-137.  
    Log cumulative constants 
Ligand Structure pKa1 pKa2 Fe3+ Al3+ Ga3+ Cu2+ Zn2+ 
3-hydroxy-1,2-dimethylpyridin-4-
one (deferiprone, 3) 
 
3.7 9.8 37.4 32.6 35.8 19.1 13.5 
3-hydroxy-1-methylpyridin-2-one 
 
  - 8.9 30.0 25.1 29.7 N/A N/A 
1-hydroxypyridin-2-one 
 
  - 5.9 27.2 21.6 N/A 13.1 12.0 
 
Under defined conditions of [Metal]total and [Ligand]total, the (relative) concentrations of 
associated chemical species over a pH range can be calculated to obtain a speciation 
plot. This is exemplified by the ferric iron in the presence and absence of deferiprone 
over the pH range 2-12 (Figure 11). In general, the higher the pM value a chelator 
possesses, the stronger its metal affinity. Bidentate chelators possessing chelating 
atoms with pKa values above 9, dominantly form metal complexes with molar ratios of 
ligand:metal of 2:1 at pH 7.4, the remaining metal coordination sites being occupied by 
water. In contrast, deferiprone (3), with pKa values of 3.7 and 9.8, forms 3:1 iron 
complexes at pH 7.4 (Figure 7).  
67 
 
A typical hexadentate 3-hydroxypyridin-4-one possesses six pKa values and one 
logK(Fe3+) value. In terms of Fe3+-complex formation and provided with suitable 
stereochemistry, a hexadentate ligand can fully coordinate a single ferric cation in a 1:1 
molar ratio.  
The determination of thermodynamic equilibrium/stability constants in complexes with a 
slow kinetics is dependent on sufficient time being allowed for the association to reach 
equilibrium after each addition, during titration studies. Metal ions possess dramatically 
different kinetic properties (Figure 12); for instance the rate constant for the substitution 
of water on iron(III) is approximately 5 log units faster than for that of aluminum(III).138 
 
 
Figure 11. Speciation plots of ferric iron in the presence and absence of deferiprone (3) 
over the pH range 2-12. (a) Ferric iron in water. (b) Ferric iron in the presence of 
deferiprone (3) under the conditions [deferiprone]total = 10-5 M and [Fe3+]total = 10-6 M. 
Charges of species are neglected for simplicity. (s): solid. 
 
(a) 
 
(b) 
 
Figure 10. Speciati n plots of ferric iron in the presence an  absence of deferiprone 
(3) over the pH range 2-12. (a) Ferric iron in water. (b) Ferric iron in the presence of 
deferiprone (3) under the conditions [deferiprone]total = 10-5 M and [Fe3+]total = 10-6 M. 
Charges of species are neglected for simplicity. (s): solid. 
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Figure 12. Logarithms of characteristic rate constants (s−1) for substitution of inner-
sphere water molecules on various metal ions.139  
 
3.2. Metal Selectivity 
Selectivity between metal ions and ligands is important for the therapeutic design of 
chelating agents. The traditional “Hard and Soft Acid and Base Principle”140 states that 
metal ions classified as soft prefer less electronegative chelating atoms, e.g. iodide, 
while metal ions classified as hard prefer more electronegative chelating atoms, e.g. 
fluoride. Ferric iron, which possesses a high charge density, is usually classified as a 
hard metal ion and prefers high charge density chelating atoms, e.g. charged oxygen 
species. In contrast, ferrous iron prefers relative low charge density chelating atoms, 
e.g. aromatic nitrogen or sulphur. Ligand Field Theory is also associated with the 
selectivity. This is highlighted here such that a transition metal ion in the presence of 
ligands with an octahedral coordination geometry will experience the splitting of the d-
shell into eg (higher energy) and t2g (lower energy) levels.139 This is especially 
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pronounced for partially-occupied d-shell metal ions, with different electron 
configurations and spin states of metal-complexes, thus leading to different stability 
constants.  
The linear free energy relationship between a single metal ion and different ligands is 
presented in Figure 8. A linear free energy relationship also exists between a single 
ligand and Z2/r of different metal ions (Figure 13), a factor which can be adopted for 
ligand design. Deferiprone (3) possesses high selectivity for ferric ion due to its two 
chelating oxygen atoms with appropriate pKa values, compared to the analogues, 3-
hydroxy-1-methylpyridin-2-one and 1-hydroxypyridin-2-one (Table 2).  
The design of hexadentate HOPOs is controlled by a number of steric effects and 
involves the choice of linker (length and type) and linking positions on the 
hydroxypyridinone ring. The combination of choices results in various pre-organised 
ligands and sterically-strained metal-complex structures, which in turn lead to different 
binding affinities.82 Hexadentate and octadentate HOPO chelators possess a high 
affinity for hard cations, for instance gallium(III), gadolinium(III) and iron(III). 
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Figure 13. Relationship between logK1 for fluoride complexes of metal ions versus Z2/r, 
where Z is the cationic charge on the metal ion, and r the ionic radius.139 ■ tetra-positive 
iron; ● tri-positive iron; ▲ di-positive iron.    
 
4. Hydroxypyridinones as chelators 
4.1. Iron(III) 
Bidentate 3,4-HOPOs have been used to chelate and sense iron in biological matrices 
for both therapeutic and analytical purposes. Deferiprone (3)141 and more recently 1-(N-
acetyl-6-aminohexyl-3-hydroxypyridin-4-one (33)142 have been developed for the 
selective removal of iron from biological tissues (Figure 14). Hexadentate 3,4-HOPOs 
have also been developed for iron scavenging, for instance tripodal ligands based on a 
tris-carboxylic acid linker (34)143 or tris-(2-aminoethylamine) (TREN) scaffold94 (35) 
(Figure 14) and compounds using KEMP as a tripodal base (16).97 The lipophilicity of 
these compounds can be readily modified by N-substitution on the pyridinone ring.96 
 
 
Figure 12. Relationship between logK1 for fluoride complexes of metal ions versus 
Z2/r, where Z is the cationic charge on the metal ion, and r the ionic radius. For 
additional metal ions see ref 135.  
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Figure 14. Compounds adopted for iron(III) chelation. 
 
4.2. Gallium(III)  
Gallium(III) possesses a similar ionic radius and surface charge density to that of 
iron(III) (Table 3) and consequently ligands that bind iron(III) also bind gallium(III) with 
similar affinity. Thus bidentate 3-hydroxypyridin-4-ones, for instance deferiprone (3), 
bind gallium(III) tightly,144 with a pGa of 20.5. A series of bidentate N-carboxyalkyl-3-
hydroxypyridin-4-ones (36) have been developed for gallium chelation in biological 
matrices (Figure 15).145 Hexadentate, tripodal 3,4-HOPOs have been designed 
specifically for gallium chelation, for instance the THP-derivative (37) (Figure 15).146 
This and related chelators find application in diagnostic therapeutics (see Section 5.1.3). 
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Figure 15. Compounds adopted for gallium(III) chelation. 
 
Table 3. Ionic properties of cations chelated by HOPOs. 
 Charge on ion Ionic Radius (Å) Surface Charge density eÅ-2 
Aluminum 3+ 0.54 0.82 
Europium 3+ 1.17 0.17 
Gallium 3+ 0.62 0.62 
Gadolinium 3+ 0.94 0.27 
Iron 3+ 0.65 0.57 
Plutonium 4+ 0.87 0.42 
Zirconium 4+ 0.72 0.62 
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4.3. Aluminum(III)       
 Aluminum(III) possesses a smaller radius than iron(III) (Table 3), which renders it one 
of the ‘hardest’ cations known, never-the-less aluminum binds to most iron(III)-chelating 
molecules, albeit with a lower affinity. Bidentate, tetradentate and hexadentate 3-
hydroxypyridin-4-ones have been used for the selective removal of aluminum from 
biological tissue.99,147-149 As expected there is an increase of pAl with denticity: 
bidentate, 16.0; tetradentate, 19.0; and hexadentate 22.0.99,147 Examples of 3,4-HOPO 
ligands developed for aluminum scavenging are presented in Figure 16. 
 
 
Figure 16. Compounds adopted for aluminum chelation. 
  
4.4. Zirconium(IV) 
By virtue of the tetrapositive nature of Zr(IV), the cation possesses a high surface 
charge density (Table 3) and so binds to hydroxypyridinones tightly. Zirconium-89 is a 
β+ emitter with desirable nuclear imaging properties, including a relatively long half life. 
Because of the larger radius and tetrapositive nature of the cation, octadentate ligands 
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have found application. The formation of a desferrioxamine / hydroxypyridinone 
conjugate (19) has proved useful in this regard.104 Guerard et al have reported a 
comparative study of the aqueous chemistry of Zr(IV) HOPO complexes,150 not 
surprisingly the 3,4-HOPO compounds were found to possess the highest affinity for 
Zr(IV). Octadentate 3,2-HOPOs (38)151 and 1,2-HOPOs (39)101 have been investigated 
and demonstrated to be capable of binding Zr(IV), but with insufficient affinity to provide 
robust complex stability in vivo. However, Buchwalder et al105 have reported that the 
tetrapodal 3,4-HOPO chelator (40) has largely overcome these problems and 
possesses a high in vivo stability (Figure 17). Hexadentate ligands have also been 
investigated for Zr(IV) binding, but for instance the tripodal 3,4-HOPO (37) 
demonstrated poor in vivo stability.152 A detailed comparison of zirconium-89 chelation 
chemistry has been reviewed by Wadas and co-workers.153,154  
 
Figure 17.  Compounds adopted for zirconium chelation.  
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4.5. Gadolinium(III)  
Among the various paramagnetic ions (Mn2+, Gd3+, Fe3+, VO2+) used as contrast agents, 
the highly paramagnetic lanthanide Gd(III), with its seven unpaired electrons and long 
electronic relaxation time, has the most favourable electronic properties as a relaxation 
agent for in vivo magnetic resonance imaging (MRI).155 MRI images are improved by 
administration of paramagnetic agents, which increase the relaxation rates of adjacent 
water protons, thereby enhancing the MRI signal. Although Gd3+ provides excellent MRI 
contrast, the high in vivo toxicity of [Gd(H2O)8]3+ necessitates that the metal is 
coordinated by high affinity chelators before it can be used in vivo.156  
The image enhancing capacity of Gd3+-based contrast agents is proportional to the 
number of water molecules which can be exchanged in the inner coordination sphere of 
the Gd3+ ion.155 The complexation of Gd3+ by organic chelators will reduce the number 
of inner sphere water molecules and therefore reduce this sensitivity. Current research 
in the field of Gd-based contrast agents focuses on obtaining micro- to nanomolar 
sensitivities, thereby reducing the toxicity due to Gd3+ accumulation. 
Hydroxypyridinones have been developed for this purpose by exploiting the relatively 
low pKa values of the chelating functions. The first ligand developed was (41), which 
forms an eight-coordinate Gd(III) centre, complexed by 6 hydroxypyridinone oxygen 
atoms and two water molecules.157 Such a complex is associated with a rapid rate of 
water-exchange, moreover the stability of the complex is higher than many of the 
oxygen/nitrogen donor complexes previously utilised for this purpose.158 In an 
analogous fashion, the tripodal 3,4-HOPO ligand presented in Figure 16 also 
76 
 
demonstrates a high thermodynamic stability for Gd(III) associated to an improved 
relaxivity (higher hydration number) of the complex.159 
 
 
 
Raymond and co-workers have systematically studied many variants on this structural 
theme.83 Hybrid ligands, for instance with terephthalic acid (42) and salicylamide (43), 
are effective relaxation agents. Hybrid ligands containing different hydroxypyridinones 
(44) also show potential.84 A further variation is to replace the TREN backbone with 
triazacyclononane (45) which provides a broader base to the Gd(III) complex (Figure 
18).88 
 
77 
 
 
Figure 18.  Compounds adopted for gadolinium chelation. 
 
4.6. Plutonium(IV) and other actinides 
Plutonium is an actinide metal used extensively in the nuclear industry. It has high 
toxicity as an alpha emitter and is readily accumulated in a range of tissues, including 
lung and bone. Pu(IV) is the most common oxidation state found in biological tissue. It 
has a high surface charge (Table 3) and so binds to iron(III) chelators, such as 
deferrioxamine and other siderophores. Tetradentate 3,2-HOPO’s, and in particular 46, 
have shown excellent potential for mobilisation of plutonium, forming 2:1 complexes,160 
as has the hexadentate 3,2-HOPO (47).160 However, a range of octadentate 
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hydroxypyridinones has been found to possess the best potential for the selective 
removal of plutonium.73,160 The two spermine backbone-derived oligo-
hydroxypyridinones (48) and (49) have been demonstrated to be particularly efficient 
Pu(III) scavengers in biological tissue (Figure 19).161,162  
HOPOs can chelate a range of actinides including thorium, americium and 
neptunium.160 
Figure19.  Compounds adopted for plutonium chelation. 
 
4.7. Europium(III) 
Organic complexes of luminescent lanthanides such as europium(III) have become 
increasingly useful for biological assays and high-throughput screening applications 
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where their long-lived luminescence leads to improvements in the signal-to-noise ratio. 
The larger radii (Table 3) renders octadentate ligands ideal for tight chelation, indeed 
the tetrapodal 1,2-HOPO (50) has proved to be an efficient chelator for europium(III).76 
The efficiency of Eu(III) luminescence by energy transfer is strongly dependent on the 
ion coordination geometry and this has been systematically modified in an attempt to 
increase the luminescence efficiency.77,100 Ligand 51 was found to be associated with 
an excellent luminescence quantum yield (Figure 20).100 
 
Figure 20.  Compounds adopted for europium chelation. 
 
5. Applications centred on HOPO chelators 
5.1. Analytical applications 
5.1.1. Fluorescence sensing 
Over the last two decades, fluorescent probes have been widely used for the selective 
quantification of metal ions because they can provide a simple, sensitive, precise and 
economical method for online monitoring of low concentrations of target metal ions 
without destruction of the biological matrix, together with the advantages of spatial and 
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temporal resolution. Several reviews regarding fluorescent probes for measuring metal 
ions (especially Zn2+, Cu2+, Fe2+ and Fe3+) in biological systems have been 
published.120,121,163  With the design of fluorescent probes, the chelating moiety should 
have the potential to selectively complex the target metal ion. The fluorophore moiety, 
which is covalently attached to the chelating moiety, should produce a distinct 
fluorescence signal upon chelation. This fluorescence change can be monitored for both 
qualitative and quantitative determination of the target metal ion. The fluorescence 
signals can be observed in three ways: decrease, increase, or shift in the fluorescence 
maxima due to either electron transfer, charge transfer or energy transfer 
processes.164,165 Fluorescence quenching, enhancement and shift is related to turn-
OFF, turn-ON and ratiometric probes chelating with the target metal ion. This process is 
generally reversible. d-Block ions such as Fe3+ often open excited state de-excitation 
pathways via electronic energy transfer and/or photoinduced electron transfer involving 
the metal center. Therefore, it is not surprising that there are many more turn-OFF 
probes that have been reported as compared to turn-ON probes. All hydroxypyridinone-
based fluorescent probes reported to date are turn-OFF probes. 
The fluorescence of hydroxypyridinone probes (52) is sensitive towards the presence of 
ferric ions,123 quenching ratios falling in the range 46-96%. The fluorescence quenching 
mechanism has been assessed and found to generate a non-linear relationship in the 
Stern-Volmer plot, indicating a static rather than dynamic mechanism of quenching. 
Further investigation of these probes led to the finding that a linear relationship exists 
between the fluorescence intensity and Fe3+ concentration when the metal-to-ligand 
ratio is less than 1:3. No additional quenching of fluorescence was observed upon 
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further increasing the metal-to-ligand ratio to greater than 1:3. Probes of the type 52 
possess a high Fe3+ and Fe2+ sensitivity (>90%) and are much less sensitive (<15%) 
towards the presence of other metal ions such as Zn2+, Ni2+, Cu+, Co2+, Ca2+, Mn2+, 
Mg2+, Na+ and K+, with the exception of Cu2+, which has a sensitivity of 40-50%.166,167 
The sensitivity towards Fe2+ is due to rapid autooxidation of iron(II) subsequent to 
coordination to the probe. The sensitivity towards Cu2+ is not a serious problem for most 
living cells, as the level of copper in the cytosol, lysosome and mitochondria is 
maintained at an extremely low level (< 10-20 M) by selective copper(II) pumps and 
chaperone proteins.168 
 
 
 
5.1.1.1. Measurement of pFe3+ values 
The fluorescence intensity of the probe in the presence of iron and a competing ligand 
is associated with the pFe3+ value of the competing ligand. A linear correlation was 
82 
 
found to exist between the fluorescence of such a mixture and the pFe3+ values of 
completing ligands. As a result of this finding, a fluorescence method was set up in 
order to determine the pFe3+ values of ligands which are difficult to measure using 
conventional spectrophotometric or potentiometric methods.169 The method can operate 
with sub-milligram quantities of competing ligand, a real advantage with natural 
products which are difficult to isolate. By using one of these fluorescent probes, ligands 
which possess pFe3+ values in the range of 17-23 can be measured. Several 
hydroxypyridinone-based hexadentate fluorescent probes were also found to be 
selective for Fe over other metals such as Cu, Zn, Ni, Mn and Co. By using one of these 
hexadentate probes (53), the pFe3+ values of a range of hexadentate chelators, 
dendrimers and polymers (which are difficult to measure by conventional 
spectrophotometric and potentiometric assays) were determined.107,170  
 
5.1.1.2. Measurement of the concentration of intracellular iron pools 
Compound 54 is a typical iron-sensitive fluorescent probe. Due to its relatively small 
molecular size (MW < 500), possession of less than 5 H-bond donors, possession of 
less than 10 H-bond acceptors and a clogP value less than 5, this probe is predicted to 
efficiently permeate biological membranes by passive diffusion.171 The permeability of 
representative probes across human erythrocyte ghost membranes was investigated 
and the rate of permeability was found to be related to the corresponding clogP 
values.123 Thus these probes have the potential for monitoring intracellular labile iron 
pools. The moderately lipophilic fluorescent probe (54) was found to be the most 
sensitive for monitoring labile iron. The concentration of the intracellular chelatable iron 
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pool in rat hepatocytes was determined, by this probe, to be 5.4 ± 1.3 μM.167 
Furthermore, this probe was used to determine the labile iron pool of human 
lymphocytes and a value of 0.57 ± 0.27 μM was determined for healthy human 
lymphocytes.172 
The lysosomal compartment of cells typically contains a relatively high level of labile 
iron but the measurement of this pool is difficult because of its small size; approximately 
1% of the cell volume. Compound 55 is a probe specifically designed to target the 
lysosome.124 The probe distribution is limited to the lysosomal compartment as 
demonstrated by colocation studies in macrophages. The fluorescence of the probe is 
highly responsive toward alterations of vesicular labile iron concentrations in the 
lysosome. This has permitted the assessment of cellular iron status with high sensitivity 
in response to the clinically applied medications desferrioxamine, deferiprone and 
deferasirox.124 Mitochondria are major utilisers of iron, as well as being an important 
source of the superoxide anion. The mitochondrial labile iron pool plays a crucial role in 
oxidative injuries and pathologies. Delocalised lipophilic cations, are able to cross the 
inner mitochondrial membrane and hence be accumulated with a distribution associated 
with the Nernst potential, typically in excess of 1000 fold.173 This useful property of 
lipophilic cations has been applied to basic hydrophobic peptides which are capable of 
targeting fluorescent iron probes to the mitochondrion. Two such hydroxypyridinone-
based fluorescent peptides (27 and 28, Scheme 30) have been designed to be 
selectively accumulated by mitochondria as confirmed by confocal microscopy.125 The 
iron-sensing ability of these two peptides was confirmed by fluorescent quenching and 
dequenching studies both in solution and in FEK4 cells.174 The probes represent the 
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first example of highly sensitive mitochondria-directed fluorescent iron chelators, with 
potential to monitor mitochondrial labile iron pool. This probe range represents a 
powerful class of sensors which are suitable for quantitative iron detection and clinical 
real-time monitoring of subcellular labile iron pools in iron-overloaded patients.124,175  
Orvig’s group have designed a range of hydroxypyridinone derivatives in order to 
investigate their interaction with amyloid protein.126 Using the fluorescent signal as the 
readout, 29b was found to be capable of interacting strongly with amyloid-beta protein 
fibrils.126  
Bicyclic lactam probes 56 and 57 have been designed to replace the established 
fluorescent probe chelator conjugates (52) by a single chemical moiety and thus a 
smaller molecular size. The quantum yields of this type of probe are higher than those 
of probes typified by 52. The relatively low pKa values of these probes result from an 
inductive effect of the amido group at the 6-position of the pyridinone ring. As a result, 
the pFe3+ values are correspondingly higher and therefore these probes bind iron 
tightly.128 The probe fluorescence is almost completely quenched in the presence of an 
equivalent amount of Fe3+ or Fe2+. In addition, these probes are also very sensitive to 
the presence of Cu2+ but much less sensitive towards other metals such as Ni2+, Co2+ 
and Mn2+. Furthermore, the combination of these probes with Zn2+, Mg2+ and Ca2+ 
results in a blue shift of the maximum emission wavelength and an increase of the 
fluorescence intensity. Although the probes can become completely quenched by the 
addition of equimolar Cu2+, the influence of this cation under in vivo conditions can be 
neglected as intracellular Cu2+ is very tightly bound to proteins and not accessible to 
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quench the probe fluorescence.176 57 was found to penetrate the cell membranes 
quickly and therefore has potential as an intracellular iron probe.127 
 
 
 
 
5.1.1.3. Measurement of the extracellular labile iron pool (‘non-transferrin bound 
iron’) 
The ability to scavenge iron from oligomeric Fe3+ citrate complexes demonstrated that 
the probes 53 and 58 scavenge iron faster than both deferiprone (3) and 
desferrioxamine (1). The limit of detection for iron by the fluorescein-based probe 58 is 
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10-8 M. However, when this direct method using either 53 or 58, was applied to various 
serum samples, the measured non-transferrin-bound iron (NTBI) concentrations were 
found to be variable, the main reason being that autofluorescence varies between 
serum samples. As the fluorescence method is so sensitive, any small change of 
fluorescence leads to a relatively large change in fluorescence emission.129 In order to 
avoid the influence of variable autofluorescence from serum samples on NTBI 
determination, it is necessary to separate the iron probe from serum during the 
fluorescence measurement. Consequently, chelating fluorescent beads (CFBs) have 
been designed which consist of various hydroxypyridinones linked to fluorescein and 
are coupled to magnetic Dynabeads®. Upon incubation with serum samples, NTBI is 
captured by the CFBs and the complex is separated from the serum proteins by flow 
cytometry by virtue of its different size.177 The autofluorescence interference is therefore 
avoided. The hexadentate pyridinone-based CFB (59) was designed as a result of a 
number of optimization steps. This probe has proved to be reliable in quantifying iron 
levels within the 0.1-10 μM range, which is the expected NTBI concentration range in 
the iron-overloaded patients.177 NTBI quantification from the sera of patients was found 
to be consistent with the known iron status of the patients. This new CFB assay has 
several advantages over other NTBI assays by virtue of its simplicity and avoidance of 
filtration steps.131 
 
5.1.2. Time-resolved luminescence sensing 
Time–resolved luminescence resonance energy transfer (TR-LRET) assays are under 
continuous development for high-throughput screening of molecular interactions178 and 
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in particular the interaction between proteins and inhibitors.179 Spectral and time 
resolved discrimination of the luminescent signal from background autofluorescence 
results in a marked improvement in sensitivity. In many assays undertaken in biological 
matrices, it is necessary to quantify a specific analyte at relatively low concentrations 
(typically 10-8M). Thus chelators are required, which possess sufficient water solubility 
and a high affinity for europium(III), such that no complex dissociation occurs even in 
the presence of the commonly used chelators EDTA and DTPA. Octadentate 
hydroxypyridinones offer this possibility, providing eight chelating oxygen atoms,180 for 
instance the tetra 1,2-HOPO (50). Optimisation of this octadentate structure in order to 
increase brightness has been achieved by removing the inner sphere water molecules 
and adjusting the geometry around the europium(III) cation by increasing the spacing 
between the two tetradentate components, using a pentoethylene oxide chain (51). This 
latter compound has potential for in vitro and cell biological measurements. 
 
5.1.3. Positron emission tomography (PET) imaging 
Positron emission tomography is a whole body diagnostic, three – dimensional 
molecular imaging modality, used in nuclear medicine that detects radiation arising from 
the decay of unstable positron emitting radioisotopes. The increasing availability of 
gallium-68 has had a significant clinical impact on the use of PET for molecular 
imaging.181 Clinical use of 68Ga receptor-targeting radiopharmaceuticals has found wide 
application in the detection of neuroendocrine cancers182 and prostate cancers.183 68Ga 
has a half-life of 68 mins. A second radioisotope, also with potential for PET imaging is 
zirconium-89, which possesses the longer half-life of 78h. 
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Both these radioisotopes bind to oxygen-rich chelators (see Sections 4.2 and 4.4) and 
two widely adopted ligands are DOTA (60) and HBED (61). Clinical radiosyntheses of 
68Ga-DOTA and 68Ga-HBED involve heating at 80 – 100°C, for 5 – 20 min at pH 3 – 5183 
followed by post-synthetic purification. In the case of DOTA, heating is required to 
speed up the complexation of 68Ga3+; for HBED, three geometric isomers result on 
gallium chelation and heating favours the formation of the thermodynamically preferred 
species. For 68Ga to be adopted for routine clinical practice, chelators that provide 
efficient and reproducible kit-based radiolabelling methods are required. Chelators 
based on 3,4-HOPOs, in contrast to those based on DOTA and HBED, allow a rapid 
one-step quantitative 68Ga3+ radiolabelling at neutral pH and ambient temperature. 
Thus, the hexadentate ligand 37 binds 68Ga3+ extremely tightly, such that there is no 
exchange with transferrin under in vivo conditions. Furthermore the 68Ga complex of 37 
is rapidly excreted via the kidneys, ensuring a low background for imaging studies.184 
 
5.1.3.1. Tris-(3,4-HOPO) bioconjugates 
The β-alanine-derived compound 62 can be functionalised for bioconjugation via 
maleimide146,152 or isothiocyanate links185,186 (63, 64 and 65). These bifunctional 
chelators can be readily coupled to peptides and proteins, for instance protein C2A,146 
C(RGDFK),185 TATE186 and Trastuzumab.184 A particularly successful application 
involves 66 which binds to prostate-specific membrane antigen (PSMA), which is over 
expressed in prostate cancer.187 The 68Ga-labelled THP-PSMA bioconjugate has been 
preclinically evaluated as a radiotracer for PSMA imaging. Interestingly, radiolabel 
procedures with 68Ga carried out by adding unprocessed generator eluate directly to a 
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vial containing the ligand THP-PSMA (66) with no further manipulation, led to efficient 
radiolabelling (i.e. 95% radiochemical yield) within 5 min, at room temperature. The 
product was a single radioactive species that demonstrated specific binding to PSMA 
protein in PSMA-expressing DU145 cells and was stable in human serum for more than 
6 h.187 Clearly, 68Ga-THP-PSMA (Galliprost®) has potential to achieve 1-step kit-based 
labelling.188 Ex vivo and in vivo PET imaging and biodistribution studies have been 
conducted in mice bearing xenografts of the same cell lines, in comparison to commonly 
used 68Ga-HBEDCC-PSMA,189 demonstrating that 68Ga-THP-PSMA selectively 
accumulates in PSMA-expressing tumours, with a good signal-to-background ratio 
delineation of PSMA-positive tumour lesions similar to the reference imaging agent. 
This compound is currently involved in clinical trials (Figure 21). Other groups have 
confirmed the clinical potential of the THP conjugate Galliprost®.190,191 In contrast to 
other 68Ga-PSMA conjugates, the extremely simple radiolabelling procedures for 68Ga-
THP-PSMA require only a generator, a cold-kit vial to be reconstituted before use, a 
syringe, quality control facilities, and shielding. These results confirm the possibility of 
generating kit-based 68Ga radiopharmaceuticals for use in hospitals and wider clinical 
contexts. 
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Figure 21. PET imaging of prostate cancer. Application of Galliprost® for patient with a 
prostate adenocarcinoma with high uptake in the primary prostate tumour and focal 
uptake in several left external iliac lymph nodes. This research was originally published 
in JNM. Hofman MS, Eu P, Jackson P, Hong E, Binns D, Iravani A, Murphy D, Mitchell 
C, Siva S, Hicks RJ, Young JD, Blower PJ, Mullen GE. Cold Kit for Prostate-Specific 
Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-
Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. J Nucl Med. 
2018;59:625-631. © SNMMI.188  
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5.1.3.2. Imaging with zirconium-89 
The larger radius of Zr4+ renders hexadentate ligands less suitable for tight chelation, 
although both DFO (1) and tripodal 3,4-HOPOs have been investigated.152,192,193 The 
stability of these complexes under in vivo conditions is not sufficient for imaging. As 
indicated in Section 4.4 tetrapodal 3,2-HOPOs and 1,2-HOPOs also lack sufficient in 
vivo stability.101,192 However the tetrapodal 3,4-HOPO (40) does largely overcome these 
problems.105 There is quantitative labelling within 10 min at room temperature.105 The 
89Zr-complex was found to be stable for over one week in human blood serum, stable in 
vivo and was excreted rapidly via urine in mice. Thus this structure would appear to be 
ideal for conjugation to targeting long-life circulating vectors such as immunoglobulins. 
 
5.1.4. Magnetic Resonance Imaging (MRI) 
As outlined in Section 4.5, complexes of Gd3+ behave as high-relaxivity MRI contrast 
agents. In particular a range of hexadentate HOPOs have been investigated in order to 
optimise solubility, proton relaxation and in vivo toxicity.83,194 However, to date none of 
these complexes have been introduced into regular clinical use, as further optimisation 
is required. Incorporation into dendrimers or attachment to macromolecules will slow 
molecular tumbling and this will increase rotational correlation times.194 Such studies 
are currently in progress. 
 
5.2. Therapeutic applications 
5.2.1. Treatment of systemic metal overload 
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Poisoning due to metal overload can result from a number of causes; excess of metal 
that is essential for life (e.g. iron), excess of metal that is not essential for life (e.g. 
aluminum) and presence of a metal that is radioactive (e.g. plutonium).195 HOPOs have 
been used therapeutically to remove excess metals belonging to each of these groups. 
 
5.2.1.1. Iron chelation 
The therapeutic chelation of iron in iron-overload patients is comparatively wide spread, 
as regular blood transfusion which leads to iron overload, is an essential treatment for 
some diseases. This is an example of systemic iron overload and is associated with the 
treatment of thalassemia major, sickle cell disease and myelodysplastic syndromes.141 
For many years DFO (1) was the only iron chelator in clinical use, but it suffered from 
the lack of oral activity and had to be administered parenterally. However a bidentate 
3,4-HOPO was introduced in the clinic in 1987,196 namely deferiprone (3) and since that 
time has been widely used to treat iron overload throughout the world. 196-201 The 
molecular weight of the iron(III) complex of deferiprone (3) is less than 500 and by virtue 
of its non-charged nature, it can readily diffuse through membranes. Thus deferiprone 
can enter cells by simple diffusion, chelate labile iron and subsequently efflux from the 
cell (Figure 22). Deferiprone complies with Lipinski’s guidelines171 and possesses 
neutral ligand and iron-complex forms at pH 7.4 (Figures 1 and 7). Bidentate 3-
hydroxypyridin-4-ones possess distribution coefficients (logDligand) which are largely 
dependent on the N-substituent. A biphasic linear relationship between the logD values 
of ligand and the corresponding iron-complex for 3-hydroxypyridin-4-ones exists (Figure 
23) – ligands with logDligand greater than or equal to -1 possess a different linear 
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relationship (eq(1)) from those with logDligand less than -1 (eq(2)). These relationships 
can be used for ligand design in order to estimate the hydrophilicity of the iron 
complexes of bidentate and hexadentate analogues. 
 
logDcomplex = 2.53 logDligand – 0.08                (1) 
logDcomplex = 0.49 logDligand – 2.45                (2) 
 
Hexadentate HOPOs have also been utilised for the scavenging and removal of toxic 
iron for instance 6743, 68202 and 69.91 None of these hexadentate ligands have entered 
clinical trials. 
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Figure 22. Mode of scavenging intracellular iron by 3,4-HOPOs, for example 
deferiprone (3). 
 
 
Figure 23. Relationship between the logD value of Fe complex (logDcomplex) and logD 
value of 3,4-HOPO (logDligand). Distribution coefficients were determined using a MOPS 
buffer (50 mM, pH 7.4)/octanol system. Reproduced with permission from Ref.38. 
Copyright 1998 American Chemical Society. 
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A range of neurodegenerative diseases are associated with the local accumulation of 
iron in different regions of the brain for instance, Alzheimer’s disease,203 Parkinson’s 
disease,204,205 multiple sclerosis,206 and pantothenate kinase-associated 
neurodegeneration (PKAN).207 Macular degeneration is associated with iron 
accumulation in retinal tissue.208 Post-mortem examination of the relevant tissue 
confirms the presence of elevated levels of iron, and also associated oxidative damage 
to lipids and proteins. Undoubtedly, this iron-induced redox damage to the tissue 
contributes to the progression of these diseases. Many bidentate 3-hydroxypyridin-4-
one derivatives have been developed for the potential treatment of 
neurodegeneration.209 However, among the three iron chelators currently approved for 
clinical use, deferiprone is the only one that can readily cross the blood brain 
barrier.210,211 Consequently, deferiprone has been investigated in animal models of the 
various diseases and in some clinical studies. With Parkinson’s disease, both animal 
models212,213 and clinical investigations have been centred on deferiprone.214,215 There 
is currently a Phase II clinical trial taking place in different European centres. 
Deferiprone has also been administered to Friedreich’s ataxia patients with the 
treatment leading to improved clinical scores.216,217 
 
5.2.1.2. Aluminum chelation 
The toxicity of aluminum is associated with anaemia, osteomalacia and some 
neurological disorders. Aluminum disrupts the homeostasis of the essential metals, iron 
and calcium. Bidentate HOPOs have been found to be effective at removing 
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aluminum,149 as have tetradentate and hexadentate HOPOs (Figure 16). However to 
date none of these compounds have been used clinically. 
 
5.2.1.3. Chelation of plutonium and other actinides 
The use of actinides in industry and defense has resulted in potential environmental and 
health issues as a large range of toxic radionucleotides, including plutonium and 
uranium, are being continuously generated. Controlled processing and the disposal of 
waste from the nuclear fuel cycle present many problems, as does nuclear weapon 
testing and potential terrorist use. By virtue of the similarities with ferric iron, plutonium 
is readily absorbed and distributed within living tissue by virtue of binding to iron 
transport proteins. It is retained in the liver, kidneys and bone.195 A large range of 
chelators have been investigated for the potential of scavenging plutonium (and related 
actinides),160 many of them being hydroxypyridinones (over 40 HOPOs are listed in 
ref160). As with iron chelators, the aim is to design orally active, non-toxic chelators with 
a powerful scavenging activity. The octadentate ligand (48), a tetra 1,2-HOPO, is the 
most likely HOPO chelator to be used for this purpose, clinically. It has successfully 
completed safety and efficacy tests in three animal species and has been approved by 
FDA for first-in-human studies. Indeed, HOPOs can remove, not only plutonium, but 
also a range of different actinides from biological tissues. Compound 48 is particularly 
effective for the removal of plutonium and thorium, compound 47 for americium and 
compound 46 for neptunium,160 thus there is the possibility of identifying ligand mixtures 
for particular accident situations.  
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5.2.2. Subcellular targeting of chelators 
It is now possible to direct iron chelators to both mitochondrial and lysosomal 
compartments (Section 5.1.1.2). At the present time these are utilised as fluorescent 
probes for the quantification of intracellular pools of labile iron,124,125 but in principle they 
can also be used as therapeutic agents. Both a tricatechol hexadentate ligand (70)218 
and its tri 3,4-HOPO-analogue (71) have been demonstrated to provide high 
photoprotection against solar ultraviolet A radiation218 of fibroblasts and thus could be a 
useful component of sunscreen formulations.  
Some diseases, for instance Friedreich’s ataxia lead to accumulation of iron specifically 
in the mitochondria.216 This genetic disease is fatal. However it has been demonstrated 
that 71 is capable of removing elevated levels of iron from such mitochondria in FEK4 
cell lines.  
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5.2.3. Photodynamic therapy 
Photodynamic therapy (PDT) is based on the activation of exogenously applied or 
endogenously formed photosensitizers by visible light in the presence of molecular 
oxygen. This process leads to the formation of singlet oxygen, which is a powerful 
oxidant, leading to the damage of subcellular organelles and cell death.219,220 5-
Aminolevulinic acid photodynamic therapy utilises the haem biosynthesis pathway to 
transiently produce elevated amounts of the natural endogenous photosensitizer, 
protoporphyrin IX. This is achieved by the addition of exogenous 5-aminolevulinic acid 
which enters the haem biosynthesis pathway.221 The stage following protoporphyrin IX 
production is the insertion of iron(II) which is catalysed by ferrochelatase, thereby 
converting protoporphyrin XI into haem. Chelation of the intracellular labile iron pool 
leads to lower levels of ferrochelatase, further enhancing the accumulation of 
protoporphyrin IX. The bidentate 3,4-HOPO (CP94, 72) has proved to be particularly 
effective in this role.222 Developing this concept further, a series of prodrugs of 5-
aminolevulinic acid (73) have been synthesised by conjugating 5-aminolevulinic acid to 
3-hydroxypyridin-4-ones.223 These compounds have the additional advantage of 
rendering the extremely hydrophilic 5-aminolevulinic more lipophilic and hence capable 
of penetrating membranes. Once inside the cell these prodrugs are rapidly hydrolysed 
by cytosolic esterases to yield 5-aminolevulinic acid and a 3,4-HOPO which is capable 
of inhibiting ferrochelatase. The most effective compound for enhancing protoporphyrin 
XI levels in KB, MCF-7 and MCF-7R cells is compound 73 (n= 10).223 This compound is 
also more effective than the prodrugs of 5-aminolevulinic acid that are currently in 
clinical use.223 
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5.2.4. Antimicrobial applications 
There are two major approaches for the design of chelator-based antimicrobial agents; 
one is centred on the exploitation of bacterial iron acquisition by the use of siderophore 
conjugates and the second is the deprivation of iron by competition with a powerful iron 
chelator. 
 
5.2.4.1. The application of siderophore conjugates 
One of the most widespread mechanisms for iron uptake by bacteria and fungi is the 
use of high affinity iron(III) chelators called siderophores.6 Siderophores are secreted in 
the environment where they scavenge iron. The resulting complexes are accumulated 
by the microorganism using an active transport system.25 Most synthetic siderophore 
conjugates utilise hydroxamates or catechols,23 although there are some that utilise 3,4-
HOPOs. Thus the monobactam MC1 (74) has excellent activity against Gram-negative 
bacteria including Pseudomonas aeruginosa and offers superior protection in an in vivo 
model of respiratory tract infection.224 In similar fashion, BAL 30072 (75) possesses 
potent activity against multidrug-resistant P. aeruginosa and Acinetobacter sp., 
including many carbapenem – resistant strains.224 
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5.2.4.2. Iron scavenging action 
Siderophore mediated transport of iron to microorganisms can be inhibited by the 
presence of chelators that possess a higher affinity for iron(III) than the endogenous 
siderophores. An essential requirement of this mechanism is that the competing 
chelator has no affinity for the iron-siderophore complex transporter. Indeed it would 
appear that many such hexadentate 3,4-HOPOs lack this property.225 Indeed 
hexadentate 3-hydroxypyridin-4-ones effectively inhibit the growth of both Gram-positive 
and Gram-negative bacteria, as well as methicillin resistant Staphyloccocus aureus 
(MRSA).95,96,226-228 The clinical potential of the combination of 3,4-HOPOs with 
antibiotics has also been reported.143  
102 
 
Chelators with strong antimicrobial activity, especially dendrimers229 and polymers119 
have potential for use as external antimicrobial agents. For instance, they could find 
application in the treatment of wound healing, especially with ulcers in the elderly. They 
may also find application in cosmetics, such as shampoos and anti-perspirants. For 
these purposes, macromolecular iron chelators, such as dendrimers and polymers, are 
assumed to have more promising potential due to their non-absorbable nature via skin, 
leading to low toxicity.119 
 
6. Conclusions 
Over the past twenty years hydroxypyridinones have emerged as important ligands for a 
wide range of metals. Each of the three types of metal-chelating hydroxypyridinone, 
namely 1-hydroxypyridin-2-one (1,2-HOPO), 3-hydroxypyridin-2-one (3,2-HOPO) and 3-
hydroxypyridin-4-one (3,4-HOPO), have found application in one or more of the 
following areas; analytical chemistry, environmental chemistry, diagnostic medicine and 
therapeutic medicine. The pyridinone ring is easily synthesised and readily converted 
into tetradentate, hexadentate and octadentate chelators. There is considerable 
potential for the control of the stereochemistry of the resulting metal complex and hence 
the properties of these multidentate molecules.  
Originally the bidentate hydroxypyridinones were investigated for their potential as orally 
active iron chelators8 and indeed one of them, deferiprone (3), a 3,4-HOPO, is currently 
used world-wide as an therapeutic agent.201 The upsurge of interest in the association 
of the inappropriate accumulation of metals in the brain (particularly iron) with a range of 
neurodegenerative diseases has led to the design of novel chelators based on the 
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HOPO structure; already deferiprone (3) is in phase 2 clinical trials for the treatment of 
Parkinson’s disease.214 
It has gradually emerged that oligomeric hydroxypyridinones have considerable 
potential as aluminum, gallium, zirconium, gadolinium, europium and plutonium 
chelators. This diversity of metals which are bound tightly to hydroxypyridinones, has 
led to many applications. Thus HOPO’s have found a role not only in scavenging iron, 
but also in scavenging aluminum and plutonium.230 Indeed, HOPOs can remove a range 
of different actinides from biological tissue and this finding has led to the possibility of 
identifying ligand mixtures for particular accident situations.160 There is a requirement 
for improved knowledge in this area, so that we will be better able to treat persons 
exposed to multiple actinides. 
Preformed HOPO complexes of gallium-68 and zirconium-89 have potential as positron 
emission tomography (PET) probes. Indeed successful clinical trials are currently in 
progress with 68Ga-THP-PSMA (Galliprost®, 66) being used to monitor patients with 
prostate cancer.188 This progress is likely to lead to the diagnosis of other cancers, for 
instance breast and pancreas. Furthermore, complexes of gallium-67, by virtue of the 
production of four gamma photons on decay, have the potential for cancer therapy. 
Preformed complexes of europium have found application in high-throughput screening 
and preformed complexes of gadolinium have potential for improving the signal to noise 
ratio in magnetic resonance imaging (MRI). The coupling of fluorescent moieties to 
bidentate 3,4-HOPOs has led to the creation of iron-sensitive fluorescent probes which 
have been utilised to monitor the labile iron pool in the cytosol, lysosome and 
mitochondria.173 Attachment of fluorescent labelled HOPOs to polymeric beads has 
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facilitated the quantification of toxic non transferrin-bound iron in thalassemia patients. 
Preliminary investigations of dendrimeric and polymeric HOPO’s have indicated their 
potential for environmental, cosmetic and clinical applications.  
These many new discoveries have demonstrated the tremendous potential of 
hydroxypyridinones as ligands for a relatively large number of hard metals. Our aim in 
preparing this review is to assist researchers in identifying suitable synthetic routes to 
both simple bidentate and multidentate HOPOs and to indicate the potential of these 
molecules in the fields of medicine, analytical science and environmental science. 
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8. Abbreviations 
AHMP = 1-(β-acrylamidoethyl)-3-hydroxy-2-methyl-pyridin-4-one 
AIBN = azobisisobutyronitrile 
ANPD = 3-(2-aminoethyl)-3-nitro-1,5-pentanediamine  
C2A = C2A domain of complement protein C2 
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CFB = chelating fluorescent bead 
CPBD = 2-cyano-2- propyl benzodithioate 
DCC = N,N'-dicyclohexylcarbodiimide 
DCM = dichloromethane 
DFO = desferrioxamine   
DIC = 1,3-diisopropylcarbodiimide 
DMAA = dimethyl acetamide 
DMF = dimethyl formamide 
DIPEA = N,N-diisopropylethylamine 
DTPA = diethylenetriaminepentaacetic acid 
DU145 = Duke University 145, human prostate cancer cell line  
EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDTA = ethylenediaminetetraacetic acid (usually as CaNa2-EDTA) 
EBAA = N,N-ethylene-bis-acrylamide 
EGDMA = ethylene glycol dimethylacrylate 
FACS = fluorescence-activated cell sorting, a specialized type of flow cytometry 
FEK4 = human dermal fibroblast cell line 
Fl = fluorophore 
Fmoc = fluorenylmethyloxycarbonyl  
GMA = glycidyl methacrylate 
HATU = 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate 
HEA = 2-hydroxyethyl acrylate 
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HEMA = hydroxyethylmethacrylate  
HOBt = hydroxybenzotriazole 
HOPO = hydroxypyridinone 
1,2-HOPO = 1-hydroxy-2-pyridinone 
3,2-HOPO = 3-hydroxy-2-pyridinone 
3,4-HOPO = 3-hydroxy-4-pyridinone 
KEMP = cis,cis-1,3,5-triamino-cis,cis-1,3,5-trimethylcyclohexane  
LDA = lithium diisopropylamide 
logD= distribution coefficient of a molecule between buffer (i.e. specific pH) and 
lipophilic phases (e.g. n-octanol) 
LTMP = lithium tetramethylpiperidide  
mCPBA = meta-chloroperoxybenzoic acid 
MRI = magnetic resonance imaging 
MRSA = methicillin-resistant Staphylococcus aureus 
NHS = N-hydroxysuccinimide 
NMM = N-methylmorpholine 
NTBI = non-transferrin-bound serum iron 
L-Orn = L-ornithine  
PAMAM = polyamidoamine 
PDI = polydispersity index 
PDT = photodynamic therapy  
PGMA = poly(glycidyl methacrylate) 
PKAN = pantothenate kinase-associated neurodegeneration 
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PPA = polyphosphoric acid 
PSMA = prostate-specific membrane antigen 
PyOxP = O-[(1-cyano-2-ethoxy-2-oxoethylidene)amino]-oxytri(pyrrolidin-1-yl) 
phosphonium hexafluorophosphate 
RAFT = reversible addition-fragmentation chain transfer 
SPPS = solid-phase peptide synthesis 
TATE = tyrosine-3-octreotate 
TBTU = 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate 
THP = hexadentate tris(3-hydroxypyridin-4-one) ligand 
TMDM = N,N,N',N'-tetramethyldiaminomethane 
TR-LRET = time-resolved luminescence resonance energy transfer 
TRAM = 1,3,5-tris(aminomethyl)benzene 
TREN = tris(2-aminoethyl)amine  
TsOH = para-toluenesulfonic acid (tosylic acid) 
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(100) D’Aléo, A.; Moore, E. G.; Xu, J.; Daumann, L. J.; Raymond, K. N. Optimization of 
the sensitization process and stability of octadentate Eu (III) 1, 2-HOPO 
complexes. Inorg. Chem. 2015, 54, 6807-6820. 
(101) Deri, M. A.; Ponnala, S.; Zeglis, B. M.; Pohl, G.; Dannenberg, J.; Lewis, J. S.; 
Francesconi, L. C. Alternative chelator for 89Zr radiopharmaceuticals: 
radiolabeling and evaluation of 3, 4, 3-(LI-1, 2-HOPO). J. Med. Chem. 2014, 57, 
4849-4860. 
114 
 
(102) Daumann, L. J.; Tatum, D. S.; Snyder, B. E.; Ni, C.; Law, G.-l.; Solomon, E. I.; 
Raymond, K. N. New insights into structure and luminescence of EuIII and SmIII 
complexes of the 3, 4, 3-LI (1, 2-HOPO) ligand. J. Am. Chem. Soc. 2015, 137, 
2816-2819. 
(103) Hou, Z.; Whisenhunt Jr, D. W.; Xu, J.; Raymond, K. N. Potentiometric, 
spectrophotometric, and 1H NMR study of four desferrioxamine B derivatives and 
their ferric complexes. J. Am. Chem. Soc. 1994, 116, 840-846. 
(104) Allott, L.; Da Pieve, C.; Meyers, J.; Spinks, T.; Ciobota, D. M.; Kramer-Marek, G.; 
Smith, G. Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89. 
Chem. Commun. 2017, 53, 8529-8532. 
(105) Buchwalder, C.; Rodriguez-Rodriguez, C.; Schaffer, P.; Karagiozov, S. K.; 
Saatchi, K.; Hafeli, U. O. A new tetrapodal 3-hydroxy-4-pyridinone ligand for 
complexation of (89)zirconium for positron emission tomography (PET) imaging. 
Dalton. Trans. 2017, 46, 9654-9663. 
(106) Cohen, S. M.; Petoud, S.; Raymond, K. N. Synthesis and metal binding 
properties of salicylate-, catecholate-, and hydroxypyridinonate-functionalized 
dendrimers. Chemistry 2001, 7, 272-279. 
(107) Zhou, T.; Neubert, H.; Liu, D. Y.; Liu, Z. D.; Ma, Y. M.; Kong, X. L.; Luo, W.; 
Mark, S.; Hider, R. C. Iron binding dendrimers: a novel approach for the 
treatment of haemochromatosis. J. Med. Chem. 2006, 49, 4171-4182. 
(108) Zhou, T.; Liu, Z. D.; Neubert, H.; Kong, X. L.; Ma, Y. M.; Hider, R. C. High affinity 
iron(III) scavenging by a novel hexadentate 3-hydroxypyridin-4-one-based 
dendrimer: synthesis and characterization. Bioorg. Med. Chem. Lett. 2005, 15, 
5007-5011. 
(109) O'Sullivan, B.; Xu, J.; Raymond, K. N. New multidentate chelators for iron. In Iron 
Chelators: New Development Strategies; Saratoga group, 2000; Vol. -; p 177-
208. 
(110) Grazina, R.; Santos, M. A. New hydroxypyridinone-functionalized Sepharoses as 
sorbing agents for hard metal ions. J. Hazard Mater. 2011, 186, 1902-1908. 
(111) Feng, M.; Van Der Does, L.; Bantjes, A. Iron (III) chelating resins II. 3-Hydroxy-4 
(1H)-pyridinones-Sepharose gels. J. Biomater. Sci. Polym. Ed. 1993, 4, 145-154. 
(112) Feng, M.; Van Der Does, L.; Bantjes, A. Iron (III) chelating resins. V. Cross‐linked 
copolymers of 1‐(β‐acrylamidoethyl)‐3‐hydroxy‐2‐methyl‐4 (1H) pyridinone 
(AHMP) and N, N‐dimethylacrylamide (DMAA) for iron (III) chelation studies. J. 
Appl. Polym. Sci. 1994, 52, 21-28. 
(113) Feng, M.-H.; van der Does, L.; Bantjes, A. Iron (III) chelating resins IV. 
Crosslinked copolymer beads of 1-(β-acrylamidoethyl)-3-hydroxy-2-methyl-4 
(1H)-pyridinone (AHMP) with 2-hydroxyethyl methacrylate (HEMA). Eur. Polym. 
J. 1994, 30, 941-947. 
(114) Li, J. P.; Olaleye, E. D.; Kong, X. L.; Zhou, T.; Ma, Y. M.; Jurach, J.; Al Rugaie, 
O.; Hider, R. C.; Zhang, G. Q.; Alsam, S.et al. Macromolecular iron-chelators via 
RAFT-polymerization for the inhibition of methicillin-resistant Staphylococcus 
aureus growth. Polymer 2016, 87, 64-72. 
(115) Moggia, F.; Fages, F.; Brisset, H.; Chaix, C.; Mandrand, B.; Levillain, E.; Roncali, 
J. Design, synthesis and electrochemical properties of a thiophene derivative 
115 
 
functionalized with a siderophore-like chelator. J. Electroanal. Chem. 2009, 626, 
42-46. 
(116) Harmatz, P.; Grady, R. W.; Dragsten, P.; Vichinsky, E.; Giardina, P.; Madden, J.; 
Jeng, M.; Miller, B.; Hanson, G.; Hedlund, B. Phase Ib clinical trial of starch-
conjugated deferoxamine (40SD02): a novel long-acting iron chelator. Br. J. 
Haematol. 2007, 138, 374-381. 
(117) Hallaway, P. E.; Eaton, J. W.; Panter, S. S.; Hedlund, B. E. Modulation of 
deferoxamine toxicity and clearance by covalent attachment to biocompatible 
polymers. Proc. Natl. Acad. Sci. U S A 1989, 86, 10108-10112. 
(118) Zhou, T.; Kong, X. L.; Liu, Z. D.; Liu, D. Y.; Hider, R. C. Synthesis and iron(III)-
chelating properties of novel 3-hydroxypyridin-4-one hexadentate ligand-
containing copolymers. Biomacromolecules 2008, 9, 1372-1380. 
(119) Zhou, Y. J.; Kong, X. L.; Li, J. P.; Ma, Y. M.; Hider, R. C.; Zhou, T. Novel 3-
hydroxypyridin-4-one hexadentate ligand-based polymeric iron chelator: 
synthesis, characterization and antimicrobial evaluation. Medchemcomm 2015, 
6, 1620-1625. 
(120) Carter, K. P.; Young, A. M.; Palmer, A. E. Fluorescent sensors for measuring 
metal ions in living systems. Chem. Rev. 2014, 114, 4564-4601. 
(121) Que, E. L.; Domaille, D. W.; Chang, C. J. Metals in neurobiology: probing their 
chemistry and biology with molecular imaging. Chem. Rev. 2008, 108, 1517-
1549. 
(122) Bennett, F. A.; Barlow, D. J.; Dodoo, A. N. O.; Hider, R. C.; Lansley, A. B.; 
Lawrence, M. J.; Marriott, C.; Bansal, S. S. L-(6,7-dimethoxy-4-coumaryl) 
alanine: an intrinsic probe for the labelling of peptides. Tetrahedron Lett. 1997, 
38, 7449-7452. 
(123) Ma, Y.; Luo, W.; Quinn, P. J.; Liu, Z.; Hider, R. C. Design, synthesis, 
physicochemical properties, and evaluation of novel iron chelators with 
fluorescent sensors. J. Med. Chem. 2004, 47, 6349-6362. 
(124) Fakih, S.; Podinovskaia, M.; Kong, X.; Collins, H. L.; Schaible, U. E.; Hider, R. C. 
Targeting the lysosome: fluorescent iron(III) chelators to selectively monitor 
endosomal/lysosomal labile iron pools. J. Med. Chem. 2008, 51, 4539-4552. 
(125) Abbate, V.; Reelfs, O.; Hider, R. C.; Pourzand, C. Design of novel fluorescent 
mitochondria-targeted peptides with iron-selective sensing activity. Biochem. J. 
2015, 469, 357-366. 
(126) Telpoukhovskaia, M. A.; Cawthray, J. F.; Rodriguez-Rodriguez, C.; Scott, L. E.; 
Page, B. D.; Patrick, B. O.; Orvig, C. 3-Hydroxy-4-pyridinone derivatives 
designed for fluorescence studies to determine interaction with amyloid protein 
as well as cell permeability. Bioorg. Med. Chem. Lett. 2015, 25, 3654-3657. 
(127) Ma, Y.; Luo, W.; Camplo, M.; Liu, Z.; Hider, R. C. Novel iron-specific fluorescent 
probes. Bioorg. Med. Chem. Lett. 2005, 15, 3450-3452. 
(128) Ma, Y. M.; Kong, X. L.; Abbate, V.; Hider, R. C. Synthesis and characterization of 
novel iron-specific bicyclic fluorescent probes. Sens. Actuators B-Chem. 2015, 
213, 12-19. 
(129) Ma, Y. M.; Hider, R. C. The selective quantification of iron by hexadentate 
fluorescent probes. Bioorg. Med. Chem. 2009, 17, 8093-8101. 
116 
 
(130) Nunes, A.; Podinovskaia, M.; Leite, A.; Gameiro, P.; Zhou, T.; Ma, Y.; Kong, X.; 
Schaible, U. E.; Hider, R. C.; Rangel, M. Fluorescent 3-hydroxy-4-pyridinone 
hexadentate iron chelators: intracellular distribution and the relevance to 
antimycobacterial properties. J. Biol. Inorg. Chem. 2010, 15, 861-877. 
(131) Sebastiani, G.; Pantopoulos, K. NTBI unveiled by chelatable fluorescent beads. 
Biochem. J. 2014, 463, e7-9. 
(132) Chen, Y. L.; Barlow, D. J.; Kong, X. L.; Ma, Y. M.; Hider, R. C. Prediction of 3-
hydroxypyridin-4-one (HPO) log K1 values for Fe(III). Dalton Trans. 2012, 41, 
10784-10791. 
(133) Crumbliss, A. L.; Harrington, J. M. Iron sequestration by small molecules: 
thermodynamic and kinetic studies of natural siderophores and synthetic model 
compounds. Adv. Inorg. Chem. 2009, 61, 179-250. 
(134) Smith, R.; Martell, A. Hydroxide ion. In Critical stability constants, Inorganic 
complexes, 1976; Vol. 4; p 7. 
(135) Ma, R.; Reibenspies, J. J.; Martell, A. E. Stabilities of 1,2-Diethyl-3-Hydroxy-4-
Pyridinone Chelates of Divalent and Trivalent Metal-Ions. Inorg. Chim. Acta 
1994, 223, 21-29. 
(136) Clarke, E. T.; Martell, A. E. 1-Methyl-3-hydroxy-2-pyridinone and 1,4-dihydroxy-2-
pyridinone complexes of the trivalent metal-ions of Fe(III), Ga(III), Al(III), In(III) 
and Gd(III) - potentiometric and spectrophotometric determination of stabilities. 
Inorg. Chim. Acta 1992, 196, 185-194. 
(137) Yue, J. L.; Martell, A. E. Potentiometric and spectrophotometric determination of 
stabilities of the 1-hydroxy-2-pyridinone complexes of trivalent and divalent metal 
ions. Inorg. Chim. Acta 1993, 214, 103-111. 
(138) Eigen, M. Fast elementary steps in chemical reaction mechanisms. Pure Appl. 
Chem. 1963, 6, 97-116. 
(139) Martell, A. E.; Hancock, R. D. Metal complexes in aqueous solutions; Springer 
Science & Business Media: New York, 1996. 
(140) Pearson, R. G.; Songstad, J. Application of the principle of hard and soft acids 
and bases to organic chemistry. J. Am. Chem. Soc. 1967, 89, 1827-1836. 
(141) Ma, Y.; Zhou, T.; Kong, X.; Hider, R. C. Chelating agents for the treatment of 
systemic iron overload. Curr. Med. Chem. 2012, 19, 2816-2827. 
(142) Pangjit, K.; Banjerdpongchai, R.; Phisalaphong, C.; Fucharoen, S.; Xie, Y. Y.; Lu, 
Z. D.; Hider, R. C.; Srichairatanakool, S. Characterisation of a novel oral iron 
chelator: 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one. J. Pharm. 
Pharmacol. 2015, 67, 703-713. 
(143) Zhu, C. F.; Qiu, D. H.; Kong, X. L.; Hider, R. C.; Zhou, T. Synthesis and in-vitro 
antimicrobial evaluation of a high-affinity iron chelator in combination with 
chloramphenicol. J. Pharm. Pharmacol. 2013, 65, 512-520. 
(144) Clevette, D. J.; Lyster, D. M.; Nelson, W. O.; Rihela, T.; Webb, G. A.; Orvig, C. 
Solution chemistry of gallium and indium 3-hydroxy-4-pyridinone complexes in 
vitro and in vivo. Inorg. Chem. 1990, 29, 667-672. 
(145) Santos, M. A.; Gil, M.; Marques, S.; Gano, L.; Cantinho, G.; Chaves, S. N-
Carboxyalkyl derivatives of 3-hydroxy-4-pyridinones: synthesis, complexation 
with Fe(III), Al(III) and Ga(III) and in vivo evaluation. J. Inorg. Biochem. 2002, 92, 
43-54. 
117 
 
(146) Berry, D. J.; Ma, Y.; Ballinger, J. R.; Tavare, R.; Koers, A.; Sunassee, K.; Zhou, 
T.; Nawaz, S.; Mullen, G. E.; Hider, R. C.et al. Efficient bifunctional gallium-68 
chelators for positron emission tomography: tris(hydroxypyridinone) ligands. 
Chem. Commun. 2011, 47, 7068-7070. 
(147) Santos, M. A.; Gama, S.; Gano, L.; Farkas, E. Bis(3-hydroxy-4-pyridinone)-EDTA 
derivative as a potential therapeutic Al-chelating agent. Synthesis, solution 
studies and biological assays. J. Inorg. Biochem. 2005, 99, 1845-1852. 
(148) Thompson, K. H.; Barta, C. A.; Orvig, C. Metal complexes of maltol and close 
analogues in medicinal inorganic chemistry. Chem. Soc. Rev. 2006, 35, 545-556. 
(149) Yokel, R. A.; Meurer, K. A.; Skinner, T. L.; Fredenburg, A. M. The 3-
hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of 
aluminum intoxication than does desferrioxamine. Drug Metab. Dispos. 1996, 24, 
105-111. 
(150) Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. 
Nat. Rev. Cancer 2002, 2, 683-693. 
(151) Tinianow, J. N.; Pandya, D. N.; Pailloux, S. L.; Ogasawara, A.; Vanderbilt, A. N.; 
Gill, H. S.; Williams, S.-P.; Wadas, T. J.; Magda, D.; Marik, J. Evaluation of a 3-
hydroxypyridin-2-one (2, 3-HOPO) based macrocyclic chelator for 89Zr4+ and its 
use for immunoPET imaging of HER2 positive model of ovarian carcinoma in 
mice. Theranostics 2016, 6, 511-521. 
(152) Ma, M. T.; Meszaros, L. K.; Paterson, B. M.; Berry, D. J.; Cooper, M. S.; Ma, Y.; 
Hider, R. C.; Blower, P. J. Tripodal tris(hydroxypyridinone) ligands for 
immunoconjugate PET imaging with (89)Zr(4+): comparison with 
desferrioxamine-B. Dalton Trans. 2015, 44, 4884-4900. 
(153) Bhatt, N. B.; Pandya, D. N.; Wadas, T. J. Recent advances in zirconium-89 
chelator development. Molecules 2018, 23, 638. 
(154) Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J. Coordinating 
radiometals of copper, gallium, indium, yttrium, and zirconium for PET and 
SPECT imaging of disease. Chem. Rev. 2010, 110, 2858-2902. 
(155) Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B. Gadolinium(III) chelates 
as MRI contrast agents: Structure, dynamics, and applications. Chem. Rev. 
1999, 99, 2293-2352. 
(156) Kumar, K.; Tweedle, M. F. Macrocyclic polyaminocarboxylate complexes of 
lanthanides as magnetic resonance imaging contrast agents. Pure Appl. Chem. 
1993, 65, 515-520. 
(157) Xu, J.; Franklin, S. J.; Whisenhunt, D. W.; Raymond, K. N. Gadolinium complex 
of tris[(3-hydroxy-1-methyl-2-oxo-1,2-didehydropyridine-4-
carboxamido)ethyl]amine - a new class of gadolinium magnetic-resonance 
relaxation agents. J. Am. Chem. Soc. 1995, 117, 7245-7246. 
(158) Helm, L.; Merbach, A. E. Water exchange on metal ions: experiments and 
simulations. Coord. Chem. Rev. 1999, 187, 151-181. 
(159) Mendonça, A. C.; Martins, A. F.; Melchior, A.; Marques, S. M.; Chaves, S.; 
Villette, S.; Petoud, S.; Zanonato, P. L.; Tolazzi, M.; Bonnet, C. S. New tris-3, 4-
HOPO lanthanide complexes as potential imaging probes: complex stability and 
magnetic properties. Dalton Transactions 2013, 42, 6046-6057. 
118 
 
(160) Gorden, A. E.; Xu, J.; Raymond, K. N.; Durbin, P. Rational design of 
sequestering agents for plutonium and other actinides. Chem. Rev. 2003, 103, 
4207-4282. 
(161) Durbin, P. W.; Kullgren, B.; Xu, J.; Raymond, K. N. Multidentate 
hydroxypyridinonate ligands for Pu (IV) chelation in vivo: comparative efficacy 
and toxicity in mouse of ligands containing 1, 2-HOPO or Me-3, 2-HOPO. Int. J. 
Radiat. Biol. 2000, 76, 199-214. 
(162) Gray, S. A.; Stradling, G. N.; Pearce, M. J.; Wilson, I.; Moody, J. C.; Burgada, R.; 
Durbin, P. W.; Raymond, K. N. Removal of plutonium and americium from the rat 
using 3,4,3-Lihopo and Dtpa after simulated wound contamination - Effect of 
delayed administration and mass of plutonium. Radiat. Prot. Dosim. 1994, 53, 
319-322. 
(163) Sahoo, S. K.; Sharma, D.; Bera, R. K.; Crisponi, G.; Callan, J. F. Iron(III) 
selective molecular and supramolecular fluorescent probes. Chem. Soc. Rev. 
2012, 41, 7195-7227. 
(164) Fan, L. J.; Zhang, Y.; Murphy, C. B.; Angell, S. E.; Parker, M. F. L.; Flynn, B. R.; 
Jones, W. E. Fluorescent conjugated polymer molecular wire chemosensors for 
transition metal ion recognition and signaling. Coord. Chem. Rev. 2009, 253, 
410-422. 
(165) Formica, M.; Fusi, V.; Giorgi, L.; Micheloni, M. New fluorescent chemosensors for 
metal ions in solution. Coord. Chem. Rev. 2012, 256, 170-192. 
(166) Luo, W.; Ma, Y. M.; Quinn, P. J.; Hider, R. C.; Liu, Z. D. Design, synthesis and 
properties of novel iron(III)-specific fluorescent probes. J. Pharm. Pharmacol. 
2004, 56, 529-536. 
(167) Ma, Y.; de Groot, H.; Liu, Z.; Hider, R. C.; Petrat, F. Chelation and determination 
of labile iron in primary hepatocytes by pyridinone fluorescent probes. Biochem. 
J. 2006, 395, 49-55. 
(168) Waldron, K. J.; Rutherford, J. C.; Ford, D.; Robinson, N. J. Metalloproteins and 
metal sensing. Nature 2009, 460, 823-830. 
(169) Ma, Y.; Xie, Y.; Hider, R. C. A novel fluorescence method for determination of 
pFe3+. Analyst 2013, 138, 96-99. 
(170) Ma, Y.; Zhou, T.; Hider, R. C. pFe(3+) determination of multidentate ligands by a 
fluorescence assay. Analyst 2015, 140, 3603-3606. 
(171) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and 
computational approaches to estimate solubility and permeability in drug 
discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23, 3-25. 
(172) Ma, Y.; Liu, Z.; Hider, R. C.; Petrat, F. Determination of the labile iron pool of 
human lymphocytes using the fluorescent probe, CP655. Anal. Chem. Insights 
2007, 2, 61-67. 
(173) Ma, Y.; Abbate, V.; Hider, R. C. Iron-sensitive fluorescent probes: monitoring 
intracellular iron pools. Metallomics 2015, 7, 212-222. 
(174) Abbate, V.; Reelfs, O.; Kong, X.; Pourzand, C.; Hider, R. C. Dual selective iron 
chelating probes with a potential to monitor mitochondrial labile iron pools. Chem. 
Commun. 2016, 52, 784-787. 
119 
 
(175) Fakih, S.; Podinovskaia, M.; Kong, X.; Schaible, U. E.; Collins, H. L.; Hider, R. C. 
Monitoring intracellular labile iron pools: A novel fluorescent iron(III) sensor as a 
potential non-invasive diagnosis tool. J. Pharm. Sci. 2009, 98, 2212-2226. 
(176) Hider, R. C.; Kong, X. Iron speciation in the cytosol: an overview. Dalton Trans. 
2013, 42, 3220-3229. 
(177) Ma, Y.; Podinovskaia, M.; Evans, P. J.; Emma, G.; Schaible, U. E.; Porter, J.; 
Hider, R. C. A novel method for non-transferrin-bound iron quantification by 
chelatable fluorescent beads based on flow cytometry. Biochem. J. 2014, 463, 
351-362. 
(178) Vogel, K. W.; Vedvik, K. L. Improving lanthanide-based resonance energy 
transfer detection by increasing donor-acceptor distances. J. Biomol. Screen. 
2006, 11, 439-443. 
(179) Bergendahl, V.; Heyduk, T.; Burgess, R. R. Luminescence resonance energy 
transfer-based high-throughput screening assay for inhibitors of essential protein-
protein interactions in bacterial RNA polymerase. Appl. Environ. Microbiol. 2003, 
69, 1492-1498. 
(180) Moore, E. G.; Samuel, A. P.; Raymond, K. N. From antenna to assay: lessons 
learned in lanthanide luminescence. Acc. Chem. Res. 2009, 42, 542-552. 
(181) Blower, P. J. A nuclear chocolate box: the periodic table of nuclear medicine. 
Dalton. Trans. 2015, 44, 4819-4844. 
(182) Hofman, M. S.; Kong, G.; Neels, O. C.; Eu, P.; Hong, E.; Hicks, R. J. High 
management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging 
neuroendocrine and other somatostatin expressing tumours. J. Med. Imaging 
Radiat. Oncol. 2012, 56, 40-47. 
(183) Afshar-Oromieh, A.; Zechmann, C. M.; Malcher, A.; Eder, M.; Eisenhut, M.; 
Linhart, H. G.; Holland-Letz, T.; Hadaschik, B. A.; Giesel, F. L.; Debus, J.et al. 
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-
choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur. J. 
Nucl. Med. Mol. Imaging. 2014, 41, 11-20. 
(184) Cusnir, R.; Imberti, C.; Hider, R. C.; Blower, P. J.; Ma, M. T. Hydroxypyridinone 
chelators: from iron scavenging to radiopharmaceuticals for PET imaging with 
gallium-68. Int. J. Mol. Sci. 2017, 18, 116. 
(185) Ma, M. T.; Cullinane, C.; Imberti, C.; Baguna Torres, J.; Terry, S. Y.; Roselt, P.; 
Hicks, R. J.; Blower, P. J. New tris (hydroxypyridinone) bifunctional chelators 
containing isothiocyanate groups provide a versatile platform for rapid one-step 
labeling and PET imaging with 68Ga3+. Bioconjug. Chem. 2015, 27, 309-318. 
(186) Ma, M. T.; Cullinane, C.; Waldeck, K.; Roselt, P.; Hicks, R. J.; Blower, P. J. Rapid 
kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a 
preliminary comparison with DOTA-Tyr(3)-octreotate. Eur. J. Nucl. Med. Mol. 
Imaging 2015, 5, 52. 
(187) Young, J. D.; Abbate, V.; Imberti, C.; Meszaros, L. K.; Ma, M. T.; Terry, S. Y. A.; 
Hider, R. C.; Mullen, G. E.; Blower, P. J. (68)Ga-THP-PSMA: a PET imaging 
agent for prostate cancer offering rapid, room-temperature, 1-step kit-based 
radiolabeling. J. Nucl. Med. 2017, 58, 1270-1277. 
(188) Hofman, M. S.; Eu, P.; Jackson, P.; Hong, E.; Binns, D.; Iravani, A.; Murphy, D.; 
Mitchell, C.; Siva, S.; Hicks, R. J.et al. Cold kit PSMA PET imaging: phase I study 
120 
 
of 68Ga-THP-PSMA PET/CT in patients with prostate cancer. J. Nuc. Med. 2018, 
59, 625-631. 
(189) Eder, M.; Schafer, M.; Bauder-Wust, U.; Hull, W. E.; Wangler, C.; Mier, W.; 
Haberkorn, U.; Eisenhut, M. 68Ga-complex lipophilicity and the targeting property 
of a urea-based PSMA inhibitor for PET imaging. Bioconjug. Chem. 2012, 23, 
688-697. 
(190) Derlin, T.; Schmuck, S.; Juhl, C.; Teichert, S.; Zörgiebel, J.; Wester, H.-J.; 
Schneefeld, S. M.; Walte, A. C.; Thackeray, J. T.; Ross, T. L. Imaging 
characteristics and first experience of [68 Ga] THP-PSMA, a novel probe for 
rapid kit-based Ga-68 labeling and PET imaging: comparative analysis with [68 
Ga] PSMA I&T. Mol. Imaging Biol. 2018, 1-9. 
(191) Derlin, T.; Schmuck, S.; Juhl, C.; Zörgiebel, J.; Schneefeld, S. M.; Walte, A. C.; 
Hueper, K.; von Klot, C. A.; Henkenberens, C.; Christiansen, H. PSA-stratified 
detection rates for [68 Ga] THP-PSMA, a novel probe for rapid kit-based 68 Ga-
labeling and PET imaging, in patients with biochemical recurrence after primary 
therapy for prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2018, 1-10. 
(192) Deri, M. A.; Ponnala, S.; Kozlowski, P.; Burton-Pye, B. P.; Cicek, H. T.; Hu, C.; 
Lewis, J. S.; Francesconi, L. C. p-SCN-Bn-HOPO: A superior bifunctional 
chelator for 89Zr immunoPET. Bioconj. Chem. 2015, 26, 2579-2591. 
(193) Evans, M. J.; Holland, J. P.; Rice, S. L.; Doran, M. G.; Cheal, S. M.; Campos, C.; 
Carlin, S. D.; Mellinghoff, I. K.; Sawyers, C. L.; Lewis, J. S. Imaging tumor burden 
in the brain with 89Zr-transferrin. J. Nucl. Med. 2013, 54, 90-95. 
(194) Werner, E. J.; Datta, A.; Jocher, C. J.; Raymond, K. N. High-relaxivity MRI 
contrast agents: where coordination chemistry meets medical imaging. Angew. 
Chem. Int. Ed. 2008, 47, 8568-8580. 
(195) Crichton, R. R.; Ward, R. J.; Hider, R. C. Metal chelation in medicine; Royal 
Society of Chemistry: Cambridge, UK, 2016. 
(196) Hoffbrand, A. V.; F, A. L.-R.; Davis, B.; Siritanakatkul, N.; Jackson, B. F.; 
Cochrane, J.; Prescott, E.; Wonke, B. Long-term trial of deferiprone in 51 
transfusion-dependent iron overloaded patients. Blood 1998, 91, 295-300. 
(197) Maggio, A.; D'Amico, G.; Morabito, A.; Capra, M.; Ciaccio, C.; Cianciulli, P.; Di 
Gregorio, F.; Garozzo, G.; Malizia, R.; Magnano, C.et al. Deferiprone versus 
deferoxamine in patients with thalassemia major: a randomized clinical trial. 
Blood Cells Mol. Dis. 2002, 28, 196-208. 
(198) Cohen, A. R.; Galanello, R.; Piga, A.; De Sanctis, V.; Tricta, F. Safety and 
effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 
2003, 102, 1583-1587. 
(199) Pepe, A.; Meloni, A.; Capra, M.; Cianciulli, P.; Prossomariti, L.; Malaventura, C.; 
Putti, M. C.; Lippi, A.; Romeo, M. A.; Bisconte, M. G.et al. Deferasirox, 
deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac 
iron and function comparison determined by quantitative magnetic resonance 
imaging. Haematologica 2011, 96, 41-47. 
(200) Baksi, A. J.; Pennell, D. J. Randomized controlled trials of iron chelators for the 
treatment of cardiac siderosis in thalassaemia major. Front. Pharmacol. 2014, 5, 
217. 
121 
 
(201) Di Maggio, R.; Maggio, A. The new era of chelation treatments: effectiveness and 
safety of 10 different regimens for controlling iron overloading in thalassaemia 
major. Br. J. Haematol. 2017, 178, 676-688. 
(202) Cohen, S. M.; O'Sulliva, B.; Raymond, K. N. Mixed hydroxypyridinonate ligands 
as iron chelators. Inorg. Chem. 2000, 39, 4339-4346. 
(203) Duce, J. A.; Bush, A. I. Biological metals and Alzheimer's disease: implications 
for therapeutics and diagnostics. Prog. Neurobiol. 2010, 92, 1-18. 
(204) Dexter, D. T.; Wells, F. R.; Agid, F.; Agid, Y.; Lees, A. J.; Jenner, P.; Marsden, C. 
D. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987, 
2, 1219-1220. 
(205) Dexter, D. T.; Wells, F. R.; Lees, A. J.; Agid, F.; Agid, Y.; Jenner, P.; Marsden, C. 
D. Increased nigral iron content and alterations in other metal ions occurring in 
brain in Parkinson's disease. J. Neurochem. 1989, 52, 1830-1836. 
(206) Lynch, S. G.; Fonseca, T.; LeVine, S. M. A multiple course trial of 
desferrioxamine in chronic progressive multiple sclerosis. Cell Mol. Biol. 2000, 
46, 865-869. 
(207) McNeill, A.; Chinnery, P. F. Neuroferritinopathy: update on clinical features and 
pathogenesis. Curr. Drug Targets 2012, 13, 1200-1203. 
(208) Hadziahmetovic, M.; Song, Y.; Wolkow, N.; Iacovelli, J.; Grieco, S.; Lee, J.; 
Lyubarsky, A.; Pratico, D.; Connelly, J.; Spino, M. The oral iron chelator 
deferiprone protects against iron overload–induced retinal degeneration. Invest. 
Ophthalmol. Vis. Sci. 2011, 52, 959-968. 
(209) Chaves, S.; Piemontese, L.; Hiremathad, A.; Santos, M. A. Hydroxypyridinone 
derivatives: a fascinating class of chelators with therapeutic applications-an 
update. Curr. Med. Chem. 2018, 25, 97-112. 
(210) Habgood, M. D.; Dehkordi, L. S.; Khodr, H. H.; Abbott, J.; Hider, R. C. 
Investigation into the correlation between the structure of hydroxypyridinones and 
blood–brain barrier permeability. Biochem. Pharmacol. 1999, 57, 1305-1310. 
(211) Hider, R. C.; Roy, S.; Ma, Y. M.; Le Kong, X.; Preston, J. The potential 
application of iron chelators for the treatment of neurodegenerative diseases. 
Metallomics 2011, 3, 239-249. 
(212) Ward, R. J.; Dexter, D.; Florence, A.; Aouad, F.; Hider, R.; Jenner, P.; Crichton, 
R. R. Brain iron in the ferrocene-loaded rat: its chelation and influence on 
dopamine metabolism. Biochem. Pharmacol. 1995, 49, 1821-1826. 
(213) Dexter, D. T.; Statton, S. A.; Whitmore, C.; Freinbichler, W.; Weinberger, P.; 
Tipton, K. F.; Della Corte, L.; Ward, R. J.; Crichton, R. R. Clinically available iron 
chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease 
after peripheral administration. J. Neural. Transm. 2011, 118, 223-231. 
(214) Devos, D.; Moreau, C.; Devedjian, J. C.; Kluza, J.; Petrault, M.; Laloux, C.; 
Jonneaux, A.; Ryckewaert, G.; Garçon, G.; Rouaix, N. Targeting chelatable iron 
as a therapeutic modality in Parkinson's disease. Antioxid. Redox Signaling 
2014, 21, 195-210. 
(215) Martin-Bastida, A.; Ward, R. J.; Newbould, R.; Piccini, P.; Sharp, D.; Kabba, C.; 
Patel, M. C.; Spino, M.; Connelly, J.; Tricta, F.et al. Brain iron chelation by 
deferiprone in a phase 2 randomised double-blinded placebo controlled clinical 
trial in Parkinson's disease. Sci. Rep. 2017, 7, 1398. 
122 
 
(216) Boddaert, N.; Le Quan Sang, K. H.; Rotig, A.; Leroy-Willig, A.; Gallet, S.; 
Brunelle, F.; Sidi, D.; Thalabard, J. C.; Munnich, A.; Cabantchik, Z. I. Selective 
iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 
110, 401-408. 
(217) Kakhlon, O.; Manning, H.; Breuer, W.; Melamed-Book, N.; Lu, C.; Cortopassi, G.; 
Munnich, A.; Cabantchik, Z. I. Cell functions impaired by frataxin deficiency are 
restored by drug-mediated iron relocation. Blood 2008, 112, 5219-5227. 
(218) Reelfs, O.; Abbate, V.; Hider, R. C.; Pourzand, C. A powerful mitochondria-
targeted iron chelator affords high photoprotection against solar ultraviolet A 
radiation. J. Invest. Dermatol. 2016, 136, 1692-1700. 
(219) Juzeniene, A.; Peng, Q.; Moan, J. Milestones in the development of 
photodynamic therapy and fluorescence diagnosis. Photochem. Photobiol. Sci. 
2007, 6, 1234-1245. 
(220) De Rosa, F. S.; Bentley, M. V. Photodynamic therapy of skin cancers: 
sensitizers, clinical studies and future directives. Pharm. Res. 2000, 17, 1447-
1455. 
(221) Kennedy, J. C.; Marcus, S. L.; Pottier, R. H. Photodynamic therapy (PDT) and 
photodiagnosis (PD) using endogenous photosensitization induced by 5-
aminolevulinic acid (ALA): mechanisms and clinical results. J. Clin. Laser Med. 
Surg. 1996, 14, 289-304. 
(222) Curnow, A.; McIlroy, B. W.; Postle-Hacon, M. J.; Porter, J. B.; MacRobert, A. J.; 
Bown, S. G. Enhancement of 5-aminolaevulinic acid-induced photodynamic 
therapy in normal rat colon using hydroxypyridinone iron-chelating agents. Br. J. 
Cancer 1998, 78, 1278-1282. 
(223) Battah, S.; Hider, R. C.; MacRobert, A. J.; Dobbin, P. S.; Zhou, T. 
Hydroxypyridinone and 5-aminolaevulinic acid conjugates for photodynamic 
therapy. J. Med. Chem. 2017, 60, 3498-3510. 
(224) Han, S.; Zaniewski, R. P.; Marr, E. S.; Lacey, B. M.; Tomaras, A. P.; Evdokimov, 
A.; Miller, J. R.; Shanmugasundaram, V. Structural basis for effectiveness of 
siderophore-conjugated monocarbams against clinically relevant strains of 
Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U S A 2010, 107, 22002-22007. 
(225) Zhou, T.; Winkelmann, G.; Dai, Z. Y.; Hider, R. C. Design of clinically useful 
macromolecular iron chelators. J. Pharm. Pharmacol. 2011, 63, 893-903. 
(226) Qiu, D. H.; Huang, Z. L.; Zhou, T.; Shen, C.; Hider, R. C. In vitro inhibition of 
bacterial growth by iron chelators. FEMS Microbiol. Lett. 2011, 314, 107-111. 
(227) Xie, Y. Y.; Liu, M. S.; Hu, P. P.; Kong, X. L.; Qiu, D. H.; Xu, J. L.; Hider, R. C.; 
Zhou, T. Synthesis, physico-chemical properties, and antimicrobial evaluation of 
a new series of iron(III) hexadentate chelators. Med. Chem. Res. 2013, 22, 2351-
2359. 
(228) Zhou, Y. J.; Liu, M. S.; Osamah, A. R.; Kong, X. L.; Alsam, S.; Battah, S.; Xie, Y. 
Y.; Hider, R. C.; Zhou, T. Hexadentate 3-hydroxypyridin-4-ones with high iron(III) 
affinity: design, synthesis and inhibition on methicillin resistant Staphylococcus 
aureus and Pseudomonas strains. Eur. J. Med. Chem. 2015, 94, 8-21. 
(229) Zhou, Y. J.; Zhang, M. X.; Hider, R. C.; Zhou, T. In vitro antimicrobial activity of 
hydroxypyridinone hexadentate-based dendrimeric chelators alone and in 
combination with norfloxacin. FEMS Microbiol. Lett. 2014, 355, 124-130. 
123 
 
(230) Durbin, P. W.; Kullgren, B.; Ebbe, S. N.; Xu, J.; Raymond, K. N. Chelating agents 
for uranium(VI): 2. Efficacy and toxicity of tetradentate catecholate and 
hydroxypyridinonate ligands in mice. Health Phys. 2000, 78, 511-521. 
 
Biographies 
Agostino Cilibrizzi – Agostino received his Ph.D. degree in Chemistry and 
Pharmaceutical Technology from the University of Florence in 2011. He is a Medicinal 
Chemist and joined the Department of Pharmaceutical Science at King’s College 
London in 2016 to work with Prof R. Hider and Dr V. Abbate. Prior to this he worked at 
the University of Florence, University of Cambridge and Imperial College London. His 
research focuses on the synthesis and medical applications of biologically active 
agents, metal chelators and optical probes for receptors and enzymes, including the 
development of bio-imaging techniques. 
 
Vincenzo Abbate – Vincenzo Abbate completed his Pharm. D. in 2004 with full marks 
(110/110 cum laude) at Federico II University of Naples. He then moved to the UK to 
undertake a PhD in Chemistry and Analytical Sciences at The Open University. In 2008 
he was awarded a prestigious Maplethorpe Fellowship of the University of London for 
the promotion of teaching and research in the pharmaceutical area. Abbate is currently 
a Lecturer in Analytical Toxicology at King’s College London (KCL) where he leads a 
research group (8 personnel) together with Professor Hider working on the design and 
synthesis of small molecules and bioactive peptides for medical applications. He is also 
the Head of R&D in the Drug Control Centre, King’s College London, where he runs a 
group of 5 scientists. He is the Director of the MSc Analytical Toxicology at KCL. Abbate 
is a Titular Member of the IUPAC Division of Chemistry and Human Health. He has 
124 
 
published over 45 papers in peer-reviewed journals, primarily in the fields of metal 
chelation and analytical toxicology. 
 
Yu-Lin Chen – Yu-Lin was born in Taiwan and received B.Eng. degree in Bio-Industrial 
Mechatronics Engineer from the National Taiwan University. After military service, he 
moved to King’s College London, where he completed his M.Sc and Ph.D. in 
Pharmaceutical Science. After a 2-year postdoctoral research with Yongmin Ma in 
Hangzhou, China, he returned to London. He has conducted research on various 
aspects of metal-chelating agents, prediction/determination of metal affinity and 
chemical lipophilicity and synthesis of hydroxypyridinones. 
 
Yongmin Ma – Professor Yongmin Ma completed his PhD degree in Medicinal 
Chemistry in 2005 under the supervision of Professor Robert Hider at King’s College 
London. He continued to work as a research fellow in Professor Hider’s group until 
2013. He was then awarded “1000-talents plan” from Zhejiang China and was 
appointed Professor at Zhejiang Chinese Medical University. His research interests 
include the design of iron chelators for the treatment of iron overload diseases and 
neurodegenerative diseases, the design of iron-specific fluorescent probes for detecting 
intracellular iron and non-transferrin bound iron. 
 
Tao Zhou – Tao Zhou received his Ph.D. degree in Organic Chemistry from Zhejiang 
University in 2001. He worked as a postdoctoral research fellow under the supervision 
of Professor Hider in King’s College London over the period January 2002 – April 2008. 
125 
 
He is currently a Professor of Medicinal Chemistry at Zhejiang Gongshang University, 
China and retains a strong research link with King’s College London. He has published 
over 90 scientific papers and 10 patents. His research interest is mainly centred on 
Medicinal Chemistry (especially design and synthesis of clinically useful metal 
chelators) and Food Science. 
 
Robert C. Hider – Robert is Professor of Medicinal Chemistry at King’s College London, 
where he has worked since 1987. Prior to this he was a Lecturer in Biological Chemistry 
at Essex University. He has worked with siderophore-based iron uptake processes in 
microorganisms and the absorption of iron by mammalian cells. His work on membrane 
structure and transport mechanisms has led to the development of novel oral iron 
chelators for the treatment of iron overload. As a result, hydroxypyridinones have been 
identified as possessing potential for clinical application. Deferiprone is now used 
worldwide for the treatment of iron overload. 
 
 
 
 
 
 
 
 
 
126 
 
TOC 
 
